Canopy Growth (CGC) 10-Q 9 Feb 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2022	Feb. 07, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Registrant Name	Canopy Growth Corporation
Entity Central Index Key	0001737927
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		494,894,047
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common shares, no par value
Trading Symbol	CGC
Security Exchange Name	NASDAQ
Entity File Number	001-38496
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	1 Hershey Drive
Entity Address, City or Town	Smiths Falls
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	K7A 0A8
City Area Code	855
Local Phone Number	558-9333
Document Quarterly Report	true
Document Transition Report	false

Condensed Interim Consolidated

Condensed Interim Consolidated Balance Sheets (Unaudited) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 598,131	$ 776,005
Short-term investments	191,119	595,651
Restricted short-term investments	12,932	12,216
Amounts receivable, net	104,640	96,443
Inventory	213,937	204,387
Prepaid expenses and other assets	52,151	52,700
Total current assets	1,172,910	1,737,402
Other financial assets	598,387	800,328
Property, plant and equipment	874,029	942,780
Intangible assets	213,530	252,695
Goodwill	142,076	1,866,503
Other assets	19,223	15,342
Total assets	3,020,155	5,615,050
Current liabilities:
Accounts payable	63,139	64,270
Other accrued expenses and liabilities	75,985	75,278
Current portion of long-term debt	455,483	9,296
Other liabilities	84,134	64,054
Total current liabilities	678,741	212,898
Long-term debt	750,118	1,491,695
Deferred income tax liabilities	8,988	15,991
Liability arising from Acreage Arrangement		47,000
Derivative liability	668	26,920
Other liabilities	141,891	190,049
Total liabilities	1,580,406	1,984,553
Commitments and contingencies
Redeemable noncontrolling interest	11,408	36,200
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 494,891,390 shares and 394,422,604 shares, respectively	7,867,310	7,482,809
Additional paid-in capital	2,510,086	2,519,766
Accumulated other comprehensive loss	(14,248)	(42,282)
Deficit	(8,937,603)	(6,370,337)
Total Canopy Growth Corporation shareholders' equity	1,425,545	3,589,956
Noncontrolling interests	2,796	4,341
Total shareholders' equity	1,428,341	3,594,297
Total liabilities and shareholders' equity	$ 3,020,155	$ 5,615,050

Condensed Interim Consolidate_2

Condensed Interim Consolidated Balance Sheets (Parenthetical) (Unaudited) - shares	Dec. 31, 2022	Mar. 31, 2022
Statement Of Financial Position [Abstract]
Common stock, shares issued	494,891,390	394,422,604

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 113,349	$ 155,024	$ 366,570	$ 456,095
Excise taxes	12,136	14,052	37,379	47,540
Net revenue	101,213	140,972	329,191	408,555
Cost of goods sold	103,654	130,882	329,203	442,367
Gross margin	(2,441)	10,090	(12)	(33,812)
Operating expenses
Selling, general and administrative expenses	122,636	116,835	351,891	355,165
Share-based compensation	6,428	6,777	21,725	35,856
Asset impairment and restructuring costs	22,259	36,439	1,794,212	128,198
Total operating expenses	151,323	160,051	2,167,828	519,219
Operating loss	(153,764)	(149,961)	(2,167,840)	(553,031)
Loss from equity method investments				(100)
Other income (expense), net	(113,340)	34,282	(406,762)	810,769
(Loss) income before income taxes	(267,104)	(115,679)	(2,574,602)	257,638
Income tax recovery (expense)	382	183	(11,587)	490
Net (loss) income	(266,722)	(115,496)	(2,586,189)	258,128
Net loss attributable to noncontrolling interests and redeemable noncontrolling interest	(5,139)	(6,571)	(19,652)	(14,307)
Net (loss) income attributable to Canopy Growth Corporation	$ (261,583)	$ (108,925)	$ (2,566,537)	$ 272,435
Basic (loss) earnings per share	$ (0.54)	$ (0.28)	$ (5.66)	$ 0.70
Basic weighted average common shares outstanding	486,112,598	393,818,282	453,237,882	390,423,083
Diluted (loss) earnings per share	$ (0.54)	$ (0.28)	$ (5.66)	$ 0.43
Diluted weighted average common shares outstanding	486,112,598	393,818,282	453,237,882	410,986,802
Comprehensive (loss) income:
Net (loss) income	$ (266,722)	$ (115,496)	$ (2,586,189)	$ 258,128
Other comprehensive income (loss), net of income tax effect
Fair value changes of own credit risk of financial liabilities	4,538	16,200	32,847	26,280
Foreign currency translation	14,921	(15,479)	24,694	(18,767)
Total other comprehensive income, net of income tax effect	19,459	721	57,541	7,513
Comprehensive (loss) income	(247,263)	(114,775)	(2,528,648)	265,641
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest	(5,139)	(6,571)	(19,652)	(14,307)
Comprehensive (loss) income attributable to Canopy Growth Corporation	$ (242,124)	$ (108,204)	$ (2,508,996)	$ 279,948

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Shareholder's Equity (Unaudited) - CAD ($) $ in Thousands	Total	Cumulative effect from adoption of ASU 2020-06	Common Shares	Additional Paid-in capital Share-based Reserve	Additional Paid-in capital Share-based Reserve Cumulative effect from adoption of ASU 2020-06	Additional Paid-in capital Warrants	Additional Paid-in capital Ownership Changes	Additional Paid-in capital Redeemable Noncontrolling Interest	Accumulated Other Comprehensive Income (Loss)	Deficit	Deficit Cumulative effect from adoption of ASU 2020-06	Noncontrolling Interests
Beginning balance at Mar. 31, 2021	$ 3,486,520		$ 7,168,557	$ 480,786		$ 2,568,438	$ (512,340)	$ (121,234)	$ (34,240)	$ (6,068,156)		$ 4,709
Other issuances of common shares and warrants	266,448		296,574	(30,126)
Replacement equity instruments from the acquisition of Supreme Cannabis	18,916			5,566		13,350
Exercise of Omnibus Plan stock options	5,455		8,690	(3,235)
Share-based compensation	35,172			35,172
Issuance and vesting of restricted share units			5,013	(5,013)
Changes in redeemable noncontrolling interest	66,600							53,500				13,100
Ownership changes relating to noncontrolling interests, net	684											684
Redemption of redeemable noncontrolling interest	(2,492)						2,617	(5,109)
Comprehensive income (loss)	265,641								7,513	272,435		(14,307)
Ending balance at Dec. 31, 2021	4,142,944		7,478,834	483,150		2,581,788	(509,723)	(72,843)	(26,727)	(5,795,721)		4,186
Beginning balance at Mar. 31, 2022	3,594,297	$ 3,723	7,482,809	492,041	$ 4,452	2,581,788	(509,723)	(44,340)	(42,282)	(6,370,337)	$ (729)	4,341
Other issuances of common shares and warrants	80,499		82,231	(1,732)
Exercise of Omnibus Plan stock options	270		1,506	(1,236)
Share-based compensation	20,892			20,892
Issuance and vesting of restricted share units and performance share units			8,993	(8,993)
Changes in redeemable noncontrolling interest	(24,791)							6,983				17,808
Ownership changes relating to noncontrolling interests, net	1,851											1,851
Redemption of redeemable noncontrolling interest	(5,092)		26,506				(2,696)	(27,350)				(1,552)
Settlement of unsecured senior notes	235,758		265,265						(29,507)
Comprehensive income (loss)	(2,528,648)								57,541	(2,566,537)		(19,652)
Ending balance at Dec. 31, 2022	$ 1,428,341		$ 7,867,310	$ 505,424		$ 2,581,788	$ (512,419)	$ (64,707)	$ (14,248)	$ (8,937,603)		$ 2,796

Condensed Interim Consolidate_5

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ (2,586,189)	$ 258,128
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment	43,185	56,467
Amortization of intangible assets	20,561	27,462
Share of loss on equity method investments		100
Share-based compensation	21,725	35,856
Asset impairment and restructuring costs	1,797,854	113,250
Income tax expense (recovery)	11,587	(490)
Non-cash fair value adjustments and charges related to settlement of unsecured senior notes	325,742	(893,024)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable	(8,197)	4,083
Inventory	(9,550)	6,702
Prepaid expenses and other assets	(6,866)	28,818
Accounts payable and accrued liabilities	(3,202)	(30,764)
Other, including non-cash foreign currency	(24,459)	(25,713)
Net cash used in operating activities	(417,809)	(419,125)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment	(6,176)	(36,620)
Purchases of intangible assets	(1,265)	(4,564)
Proceeds on sale of property, plant and equipment	10,894	25,660
Redemption of short-term investments	415,322	340,218
Net cash proceeds on sale of subsidiaries	12,432	10,324
Investment in other financial assets	(67,186)	(374,414)
Net cash outflow on acquisition of subsidiaries	(24,223)	(14,947)
Other investing activities	2,327	(16,759)
Net cash provided by (used in) investing activities	342,125	(71,102)
Cash flows from financing activities:
Proceeds from issuance of common shares and warrants	856	1,460
Proceeds from exercise of stock options	270	5,455
Repayment of long-term debt	(117,951)	(50,217)
Other financing activities	(29,096)	(3,036)
Net cash used in financing activities	(145,921)	(46,338)
Effect of exchange rate changes on cash and cash equivalents	43,731	(2,942)
Net decrease in cash and cash equivalents	(177,874)	(539,507)
Cash and cash equivalents, beginning of period	776,005	1,154,653
Cash and cash equivalents, end of period	598,131	615,146
Cash received during the period:
Income taxes	4,709	993
Interest	20,140	10,844
Cash paid during the period:
Income taxes	1,099	2,641
Interest	95,267	83,968
Noncash investing and financing activities
Additions to property, plant and equipment	$ 425	$ (5,145)

Description of Business

Description of Business	9 Months Ended
	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1 . DESCRIPTION OF BUSINESS Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario. References herein to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its subsidiaries. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act , which came into effect on October 17, 2018 and regulates both the medical and adult-use cannabis markets in Canada. The Company has also expanded to jurisdictions outside of Canada where cannabis and/or hemp is federally permissible and regulated, and the Company, through its subsidiaries, operates in the United States, Germany, and certain other global markets. Additionally, the Company produces, distributes and sells a range of other consumer products globally, including vaporizers; beauty, skincare, wellness and sleep products; and sports nutrition beverages.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	2 . BASIS OF PRESENTATION These condensed interim consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Canopy Growth has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars. Our condensed interim consolidated financial statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. Certain information and footnote disclosures normally included in the audited annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted or condensed. These condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022 (the “Annual Report”) and have been prepared on a basis consistent with the accounting policies as described in the Annual Report. These condensed interim consolidated financial statements are unaudited and reflect adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods in accordance with U.S. GAAP. The results reported in these condensed interim consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for an entire fiscal year. The policies set out below are consistently applied to all periods presented, unless otherwise noted. Principles of consolidation The accompanying condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 21 . Use of estimates The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates. New accounting policies Recently Adopted Accounting Pronouncements Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06 , Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by removing the separation models for convertible debt instruments and convertible preferred stock with (1) cash conversion features, and (2) beneficial conversion features. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company adopted the guidance on April 1, 2022, using the modified retrospective approach with the cumulative effect recognized as an adjustment to the opening deficit balance, and, accordingly, prior period balances and disclosures have not been restated. Upon adoption of ASU 2020-06, the Supreme Debentures (as defined below) will be accounted for under the separation model for a substantial premium instead of a beneficial conversion feature resulting in an increased debt discount to be amortized over the life of the instrument. The adoption of this guidance resulted in increased additional paid-in capital by $ 4,452 , decreased long-term debt by $ 3,723 , and decreased accumulated deficit by $ 729 for non-cash accretion expense prior to April 1, 2022.

Canopy USA

Canopy USA	9 Months Ended
	Dec. 31, 2022
Reorganizations [Abstract]
Canopy USA	3 . CANOPY USA Reorganization - Creation of Canopy USA On October 24, 2022, Canopy Growth completed a number of strategic transactions in connection with the creation of a new U.S.-domiciled holding company, Canopy USA, LLC ("Canopy USA") (the "Reorganization"). Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by Canopy Growth, which is expected to enable Canopy USA, following, among other things, the Meeting (as defined below) and the exercise of the Acreage Option (as defined below), including the issuance of the Fixed Shares (as defined below) to Canopy USA, to consummate the acquisitions of Acreage Holdings, Inc. ("Acreage"), Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, "Wana"), and Lemurian, Inc. ("Jetty"). Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA has an ownership interest in the following assets, among others: • Wana - The option to acquire 100 % of the membership interests of Wana (the "Wana Option"), a leading cannabis edibles brand in North America. • Jetty - The option to acquire 100 % of the shares of Jetty (the "Jetty Option"), a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology. Canopy Growth currently retains the option to acquire the issued and outstanding Class E subordinate voting shares (the “Fixed Shares”) of Acreage (the "Acreage Option"), representing approximately 70 % of the total shares of Acreage, at a fixed share exchange ratio of 0.3048 of a common share of Canopy Growth per Fixed Share. Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, the Fixed Shares will be issued to Canopy USA. In addition, Canopy USA has agreed to acquire all of the issued and outstanding Class D subordinate voting shares of Acreage (the “Floating Shares”) by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.45 of a common share of Canopy Growth for each Floating Share held. Acreage is a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S. including New Jersey and New York. In addition, as of October 24, 2022, Canopy USA holds direct and indirect interests in the capital of TerrAscend Corp. ("TerrAscend"), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland. Canopy USA's direct and indirect interests in TerrAscend includes: (i) 38,890,570 exchangeable shares in the capital of TerrAscend (the "TerrAscend Exchangeable Shares"), an option to purchase 1,072,450 TerrAscend common shares (the "TerrAscend Common Shares") for an aggregate purchase price of $ 1.00 (the "TerrAscend Option") and 22,474,130 TerrAscend Common Share purchase warrants previously held by Canopy Growth (the "TerrAscend Warrants"); and (ii) the debentures and loan agreement between Canopy Growth and certain TerrAscend subsidiaries. On December 9, 2022, Canopy USA and certain limited partnerships that are controlled by Canopy USA entered into a debt settlement agreement with TerrAscend and certain of its subsidiaries whereby all of the debt obligations, including all principal and interest, were extinguished and all of the previously issued TerrAscend Warrants controlled by Canopy USA were cancelled in exchange for the issuance of 24,601,467 TerrAscend Exchangeable Shares and 22,474,130 new TerrAscend Warrants expiring on December 31, 2032 . See Note 10 for further details. Canopy USA was determined to be a variable interest entity ("VIE") pursuant to Accounting Standards Codification ("ASC") 810 - Consolidations and Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth has consolidated the financial results of Canopy USA. Ownership of U.S. Cannabis Investments Following the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held, directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities, other than the Acreage Option. Canopy Growth holds non-voting and non-participating shares (the "Non-Voting Shares") in the capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA, but are convertible into Class A common shares of Canopy USA (the “Canopy USA Common Shares”). The Company also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint two members to the Canopy USA board of managers. On October 24, 2022, Canopy USA issued 1,000,000 Canopy USA Common Shares to VCo Ventures LLC (“VCo Ventures”), a former shareholder of Jetty, in exchange for US$ 1,000 . Agustin Huneeus Jr. is the manager of VCo Ventures. Following the closing of the investment, a wholly-owned subsidiary of the Company holds Non-Voting Shares in the capital of Canopy USA, representing approximately 99.3 % of the issued and outstanding shares in Canopy USA on an as-converted basis. Canopy USA retains a call right (the “Repurchase Right”) to repurchase all shares of Canopy USA that have been issued to VCo Ventures at a price per Canopy USA Common Share equal to the greater of fair market value as determined by an appraiser appointed by Canopy USA and US$ 2,000 in the aggregate; provided that if the repurchase occurs prior to March 31, 2023 , the Repurchase Right can be exercised at the initial subscription price. VCo Ventures has also been granted the right to appoint one member to the Canopy USA board of managers and a put right following the conversion of the Non-Voting Shares into Canopy USA Common Shares on the same terms and conditions as the Repurchase Right. On October 24, 2022, Canopy USA and the Company also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana Option and the future payments owed in connection with the exercise of the Wana Option will be reduced to US$ 3.00 in exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, Canopy USA Common Shares and Canopy Growth common shares will be issued to the shareholders of Wana, each with a value equal to 7.5 % of the fair market value of Wana as of January 1, 2023. The value of Wana and the number of Canopy USA Common Shares will be determined based on the fair market value of Wana and the Canopy USA Common Shares, respectively, as determined by an appraiser appointed by the Company and an appraiser appointed by the shareholders of Wana (and, if required, a third appraiser to be appointed by the initial two appraisers). The Canopy USA Common Shares and Canopy Growth common shares will only be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, after January 1, 2023 and only if CBG Holdings LLC (“CBG”) and Greenstar Canada Investment Limited Partnership (“Greenstar”), indirect, wholly-owned subsidiaries of Constellation Brands, Inc. (“CBI”), have converted their Canopy Growth common shares into Exchangeable Shares (as defined below). The Wana Amending Agreement may be terminated and no Canopy USA Common Shares or Canopy Growth common shares will be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman in the event that CBG and Greenstar have not converted their Canopy Growth common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) March 31, 2023. The Canopy USA Common Shares issuable to Ms. Whiteman, or entities controlled by Ms. Whiteman, will also be subject to a repurchase right (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the greater of fair market value as determined by an appraiser and the initial subscription price multiplied by an accrued annual interest rate of 10 %. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA board of managers and a put right on the same terms and conditions as the Wana Repurchase Right. Canopy Growth and Canopy USA have also entered into a protection agreement (the "Protection Agreement") to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting Shares are converted into Canopy USA Common Shares but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USA . Upon closing of Canopy USA's acquisition of Acreage, Canopy Growth will receive additional Non-Voting Shares from Canopy USA in consideration for the issuance of common shares of the Company that shareholders of Acreage will receive in accordance with the terms of the Existing Acreage Arrangement Agreement (as defined below) and the Floating Share Arrangement Agreement. In addition, subject to the terms and conditions of the Protection Agreement and the terms of the option agreements to acquire Wana and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty. Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA Common Shares, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth. Acreage Agreements On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage (the "Floating Share Arrangement Agreement"), pursuant to which, subject to approval of the holders of the Floating Shares and the terms and conditions of the Floating Share Arrangement Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of a court-approved plan on arrangement (the "Floating Share Arrangement") in exchange for 0.45 of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, the Company has irrevocably waived the Acreage Floating Option (as defined below) existing under the Existing Acreage Arrangement Agreement. It is expected that the Floating Share Arrangement will be effected by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia). The Floating Share Arrangement requires the approval of: (i) at least two-thirds of the votes cast by the holders of the Floating Shares; and (ii) at least a majority of the votes cast by the holders of the Floating Shares, excluding the votes cast by "interested parties" and "related parties" (as such terms are defined in Multilateral Instrument 61-101 - Protection Of Minority Security Holders In Special Transactions ), at a special meeting of Acreage shareholders. On October 24, 2022, Canopy Growth and Canopy USA entered into voting support agreements with certain of Acreage's directors, officers and consultants pursuant to which such persons have agreed, among other things, to vote their Floating Shares in favor of the Floating Share Arrangement, representing approximately 7.3 % of the issued and outstanding Floating Shares. In addition to shareholder and court approvals, the Floating Share Arrangement is subject to approval of the Amendment Proposal (as defined below) and applicable regulatory approvals including, but not limited to, Toronto Stock Exchange approval and the satisfaction of certain other closing conditions customary in transactions of this nature. Assuming timely receipt of all necessary court, shareholder, regulatory and other third-party approvals and the satisfaction of all other conditions, closing of the acquisition of Acreage is expected to occur in late 2023. It is intended that Canopy Growth's existing option to acquire the Fixed Shares on the basis of 0.3048 of a Company common share per Fixed Share will be exercised after the Meeting in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the "Existing Acreage Arrangement Agreement"). Canopy Growth will not hold any Fixed Shares or Floating Shares. Completion of the acquisition of the Fixed Shares following exercise of the option is subject to the satisfaction of certain conditions set forth in the Existing Acreage Arrangement Agreement. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement is anticipated to occur immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement in late 2023 such that 100 % of the issued and outstanding shares of Acreage will be owned by Canopy USA on closing of the acquisition of both the Fixed Shares and the Floating Shares. In addition, the Company entered into additional agreements related to Acreage that are described in Note 10. Special Shareholder Meeting In connection with the Reorganization, Canopy Growth expects to hold a special meeting of shareholders (the "Meeting") at which Canopy Growth shareholders will be asked to consider and, if deemed appropriate, to pass a special resolution authorizing an amendment to its articles of incorporation, as amended (the "Amendment Proposal"), in order to: (i) create and authorize the issuance of an unlimited number of a new class of non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the “Exchangeable Shares”); and (ii) restate the rights of the Company's common shares to provide for a conversion feature whereby each common share may at any time, at the option of the holder, be converted into one Exchangeable Share. The Exchangeable Shares will not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy Growth but will be convertible into common shares. The Amendment Proposal must be approved by at least 66 ⅔% of the votes cast on a special resolution by Canopy Growth's shareholders present in person or represented by proxy at the Meeting. On October 24, 2022, CBG and Greenstar entered into a voting and support agreement with Canopy Growth (the “Voting and Support Agreement”). Pursuant to the terms of the Voting and Support Agreement, CBG and Greenstar agreed, subject to the terms and conditions thereof, among other things, to vote all of the Canopy Growth common shares beneficially owned, directed or controlled, directly or indirectly, by them for the Amendment Proposal. In the event the Amendment Proposal is approved, and subject to the conversion by CBI of their Canopy Growth common shares into Exchangeable Shares, Canopy USA is expected to exercise the Wana Option and the Jetty Option. In the event the Amendment Proposal is not approved, Canopy USA will not be permitted to exercise its rights to acquire shares of Acreage, Wana or Jetty and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy will retain its option to acquire the Fixed Shares under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Option and the Jetty Option, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the Company is contractually required to cause Canopy USA to exercise its Repurchase Right to acquire the Canopy USA Common Shares held by the third party investors, being the Canopy USA Common Shares held by VCo Ventures. Balance Sheet Actions On October 24, 2022, Canopy Growth entered into agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021 (the "Credit Agreement") pursuant to which Canopy Growth will tender US$ 187,500 of the principal amount outstanding thereunder at a discounted price of US$ 930 per US$ 1,000 or US$ 174,375 in the aggregate (the "Paydown"). The first payment of $ 117,528 (US $ 87,852 ) was made on November 10, 2022 to reduce the principal indebtedness by $ 126,324 (US $ 94,427 ). The second payment pursuant to the Paydown is required to be made by no later than April 17, 2023. See Note 15 for further details. Canopy Growth also agreed with its lenders to amend certain terms of the Credit Agreement (collectively, the "Credit Agreement Amendments"). The Credit Agreement Amendments include, among other things: (i) reductions to the minimum Liquidity (as defined in the Credit Agreement) covenant to US$ 100,000 , which is to be further reduced as payments are made in accordance with the Paydown; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$ 100,000 ; and (iv) the elimination of the additional US$ 500,000 incremental term loan facility. Relationship with CBI In connection with the Reorganization, CBI has indicated its current intention to convert all of its common shares of the Company into Exchangeable Shares, conditional upon the approval of the Amendment Proposal. However, any decision to convert will be made by CBI in its sole discretion, and CBI is not obligated to effect any such conversion. In connection with the foregoing, on October 24, 2022, Canopy Growth entered into a consent agreement with CBG and Greenstar (the “Consent Agreement”), pursuant to which the parties agreed, among other things, that following the conversion by CBG and Greenstar of their respective Canopy Growth common shares into Exchangeable Shares, other than the Consent Agreement and the termination rights contained therein and the 4.25 % unsecured senior Canopy Growth notes due in 2023 (the "Notes") held by Greenstar, all agreements between Canopy Growth and CBI, including the Second Amended and Restated Investor Rights Agreement, dated as of April 18, 2019, by and among certain wholly-owned subsidiaries of CBI and Canopy Growth (the "Second Amended and Restated Investor Rights Agreement"), will be terminated. Pursuant to the terms of the Consent Agreement, CBG and Greenstar also agreed, among other things, that at the time of the conversion by CBG and Greenstar of their Canopy Growth common shares into Exchangeable Shares, (i) CBG will surrender the warrants held by CBG to purchase 139,745,453 common shares for cancellation for no consideration; and (ii) all nominees of CBI that are currently sitting on the board of directors of Canopy Growth (the "Board") will resign from the Board. In addition, pursuant to the Consent Agreement, Canopy Growth is contractually required to convert its Non-Voting Shares into Canopy USA Common Shares and cause Canopy USA to repurchase the Canopy USA Common Shares held by certain third-party investors in Canopy USA in the event CBG and Greenstar have not converted their respective common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) February 28, 2023 (the “Termination Date”). The Consent Agreement will automatically terminate on the Termination Date. In the event that CBI does not convert its Canopy Growth common shares into Exchangeable Shares, Canopy USA will not be permitted to exercise its rights to acquire the Fixed Shares, Wana or Jetty, and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy Growth will retain its option to acquire the Fixed Shares under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Option and the Jetty Option, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the Company is contractually required to cause Canopy USA to exercise its Repurchase Right to acquire the Canopy USA Common Shares held by the third party investors, being the Canopy USA Common Shares held by VCo Ventures. Potential Changes to Canopy USA Structure The Company is committed to both optimizing the value of Canopy USA and remaining in compliance with the Nasdaq Stock Market (the "Nasdaq") listing requirements. Accordingly, while Canopy Growth remains in discussions with the Nasdaq and another exchange with respect to its ongoing listing despite the consolidation of the financial results of Canopy USA with the Company’s financial results, the Company is prepared to make changes to the structure of its interest in Canopy USA such that Canopy Growth would not be required to consolidate the financial results of Canopy USA into Canopy Growth’s financial statements, which may include: (1) reducing Canopy Growth’s economic interest in Canopy USA on an as-converted basis to no greater than 90%; (2) reducing the number of managers on Canopy USA’s board of managers from four to three, including, reducing Canopy Growth’s nomination right to a single manager; (3) modifying the terms of the Protection Agreement and Canopy USA’s Limited Liability Company Agreement in order to eliminate certain negative covenants; and (4) modifying the terms of the agreements with third-party investors in Canopy USA to, among other things, eliminate their right to guaranteed returns .

Asset Impairment and Restructur

Asset Impairment and Restructuring Costs	9 Months Ended
	Dec. 31, 2022
Restructuring And Related Activities [Abstract]
Asset Impairment and Restructuring Costs	4 . ASSET IMPAIRMENT AND RESTRUCTURING COSTS Three months ended June 30, 2022 In the three months ended June 30, 2022, the Company performed a quantitative goodwill impairment assessment for the cannabis operations reporting unit in the global cannabis segment, and recognized impairment losses totaling $ 1,725,368 . Refer to Note 13 for further details. Additionally, in the three months ended June 30, 2022, the Company recognized incremental costs primarily associated with the restructuring actions completed in the year ended March 31, 2022, including the closure of certain of its Canadian production facilities, and other operational changes initiated in the three months ended March 31, 2022 to: (i) implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business, and (ii) implement a flexible manufacturing platform, including contract manufacturing for certain product formats. Three months ended September 30, 2022 In the three months ended September 30, 2022, the Company recorded asset impairment and restructuring costs primarily related to: • Impairment losses associated with the divestiture of the Company's Canadian retail operations pursuant to the OEGRC Transaction and the FOUR20 Transaction (as each term is defined below), as described in Note 28 below. In connection with this divestiture, the Company recorded write-downs of property, plant and equipment, operating licenses and brand intangible assets, right-of-use assets, and certain other assets due to the excess of their carrying values over their estimated fair values. • Incremental costs primarily associated with the restructuring actions completed in the year ended March 31, 2022, including the closure of certain of the Company's Canadian production facilities. • Goodwill impairment losses of $ 2,311 associated with one of the Company's reporting units (refer to Note 13 for further details) and asset impairment charges relating to certain acquired brand intangible assets. Three months ended December 31, 2022 In the three months ended December 31, 2022, the Company recorded asset impairment and restructuring costs primarily related to: • Asset impairment charges totaling $ 10,600 relating to certain acquired brand intangible assets within our Canada cannabis segment. • Employee-related restructuring charges associated with actions completed in the three months ended December 31, 2022 as part of the Company's ongoing program to align general and administrative costs with business objectives, and further streamline the Company's operations. • Incremental impairment losses associated with the divestiture of the Company's Canadian retail operations, as described above and in Note 28, as the Company recorded write-downs of certain other assets due to the excess of their carrying values over their estimated fair values, and recognized contractual and other settlement obligations. • Incremental costs primarily associated with the restructuring actions completed in the year ended March 31, 2022, including the closure of certain of the Company's Canadian production facilities. As a result, in the three and nine months ended December 31, 2022, the Company recognized asset impairment and restructuring costs of $ 22,259 and $ 1,794,212 , respectively (three and nine months ended December 31, 2021 – $ 36,439 and $ 128,198 , respectively).

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Dec. 31, 2022
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	5 . CASH AND CASH EQUIVALENTS The components of cash and cash equivalents are as follows: December 31, March 31, 2022 2022 Cash $ 524,979 $ 470,682 Cash equivalents 73,152 305,323 $ 598,131 $ 776,005

Short-term Investments

Short-term Investments	9 Months Ended
	Dec. 31, 2022
Short Term Investments [Abstract]
Short-term Investments	6 . SHORT-TERM INVESTMENTS The components of short-term investments are as follows: December 31, March 31, 2022 2022 Term deposits $ 98,286 $ 319,092 Asset-backed securities 80,924 21,905 Government securities - 22,253 Commercial paper and other 11,909 232,401 $ 191,119 $ 595,651 The amortized cost of short-term investments at December 31, 2022 is $ 193,537 (March 31, 2022 – $ 599,862 ).

Amounts Receivable, Net

Amounts Receivable, Net	9 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Amounts Receivable, Net	7 . AMOUNTS RECEIVABLE, NET The components of amounts receivable, net are as follows: December 31, March 31, 2022 2022 Accounts receivable, net $ 85,297 $ 78,059 Indirect taxes receivable 7,835 7,524 Interest receivable 2,585 4,406 Other receivables 8,923 6,454 $ 104,640 $ 96,443 Included in the accounts receivable, net balance at December 31, 2022 is an allowance for doubtful accounts of $ 6,477 (March 31, 2022 – $ 4,764 ).

Inventory

Inventory	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	8 . INVENTORY The components of inventory are as follows: December 31, March 31, 2022 2022 Raw materials, packaging supplies and consumables $ 34,940 $ 26,821 Work in progress 64,483 65,245 Finished goods 114,514 112,321 $ 213,937 $ 204,387 In the three and nine months ended December 31, 2022, the Company recorded write-downs related to inventory in cost of goods sold of $ 9,820 and $ 32,978 , respectively (three and nine months ended December 31, 2021 – $ 11,811 and $ 104,662 , respectively).

Prepaid Expenses and Other Asse

Prepaid Expenses and Other Assets	9 Months Ended
	Dec. 31, 2022
Prepaid Expense And Other Assets Current [Abstract]
Prepaid Expenses and Other Assets	9 . PREPAID EXPENSES AND OTHER ASSETS The components of prepaid expenses and other assets are as follows: December 31, March 31, 2022 2022 Prepaid expenses $ 28,736 $ 23,041 Deposits 7,740 10,145 Prepaid inventory 786 449 Other assets 14,889 19,065 $ 52,151 $ 52,700

Other Financial Assets

Other Financial Assets	9 Months Ended
	Dec. 31, 2022
Schedule Of Investments [Abstract]
Other Financial Assets	. OTHER FINANCIAL ASSETS The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 22. Foreign Balance at currency Balance at March 31, Fair value translation December 31, Entity Instrument 2022 Additions changes adjustments Other 2022 Acreage 1 Option $ - $ - $ 37,000 $ - $ - $ 37,000 TerrAscend Exchangeable Shares Exchangeable shares 229,000 51,000 ( 207,000 ) - - 73,000 TerrAscend Canada - October 2019 Term loan / debenture 10,280 - ( 146 ) - ( 10,134 ) - TerrAscend Canada - March 2020 Term loan / debenture 49,890 - ( 4,804 ) - ( 45,086 ) - Arise Bioscience Term loan / debenture 13,343 - ( 1,767 ) 1,268 ( 12,844 ) - TerrAscend - October 2019 Warrants 3,730 - ( 3,372 ) - ( 358 ) - TerrAscend - March 2020 Warrants 60,740 - ( 46,376 ) - ( 14,364 ) - TerrAscend - December 2020 Warrants 3,460 - ( 2,246 ) - ( 1,214 ) - TerrAscend - December 2022 Warrants - 33,000 ( 17,500 ) - - 15,500 TerrAscend Option 6,300 - ( 5,050 ) - - 1,250 Wana Option 372,343 - ( 135,405 ) 22,398 - 259,336 Jetty Options - 90,120 ( 9,778 ) 5,048 - 85,390 Acreage Hempco 1 Debenture 28,824 - 874 2,373 ( 4,218 ) 27,853 Acreage Debt Option Premium Option - 38,048 - 581 - 38,629 Acreage Tax Receivable Agreement Other - 41,491 - ( 231 ) - 41,260 Other - at fair value through net income (loss) Various 10,396 - ( 1,185 ) 524 - 9,735 Other - classified as held for investment Loan receivable 12,022 - - - ( 2,588 ) 9,434 $ 800,328 $ 253,659 $ ( 396,755 ) $ 31,961 $ ( 90,806 ) $ 598,387 1 See Note 29 for information regarding the Acreage Arrangement and Acreage Hempco. For information regarding the Reorganization, see Note 3 . Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds an ownership interest in certain U.S. cannabis investments previously held by the Company, including, among others, interests in the Floating Shares of Acreage, Wana, Jetty, and TerrAscend. TerrAscend Arrangement On December 9, 2022, Canopy USA and certain limited partnerships that are controlled by Canopy USA entered into a debt settlement agreement (the “TerrAscend Settlement Agreement”) with TerrAscend, TerrAscend Canada Inc. ("TerrAscend Canada") and Arise BioScience, Inc. ("Arise BioScience", together with TerrAscend and TerrAscend Canada, the "TerrAscend Entities") whereby $ 125,467 in aggregate loans, including accrued interest thereon, payable by certain subsidiaries of TerrAscend were extinguished and 22,474,130 TerrAscend Warrants, being all of the previously issued TerrAscend Warrants controlled by Canopy USA (the “Prior Warrants”) were cancelled in exchange for the issuance of: (i) 24,601,467 TerrAscend Exchangeable Shares at a notional price of $ 5.10 per TerrAscend Exchangeable Share; and (ii) 22,474,130 new TerrAscend Warrants (the "New Warrants" and, together with the TerrAscend Exchangeable Shares, the "New TerrAscend Securities") with a weighted average exercise price of $ 6.07 per TerrAscend Common Share and expiring on December 31, 2032 (collectively, the "TerrAscend Arrangement"). Following the issuance of the New TerrAscend Securities, Canopy USA beneficially owns: (i) 63,492,037 TerrAscend Exchangeable Shares; (ii) 22,474,130 New Warrants; and (iii) t he TerrAscend Option. The TerrAscend Exchangeable Shares can be converted into TerrAscend Common Shares at Canopy USA's option, subject to the terms of the Protection Agreement. On December 9, 2022, the estimated fair value of the financial instruments that were derecognized from these consolidated financial statements was $ 89,094 , consisting of: (i) the aggregate term loans or debentures that were extinguished, including accrued interest, with an estimated fair value of $ 72,191 ; and (ii) the Prior Warrants that were cancelled, with an estimated fair value of $ 16,903 . Changes in the estimated fair value of these financial instruments up to December 9, 2022 were recorded in other income (expense), net. On December 9, 2022, the estimated fair value of the financial instruments that were received from the TerrAscend Entities was $ 84,000 , consisting of: (i) 24,601,467 TerrAscend Exchangeable Shares with an estimated fair value of $ 51,000 ; and (ii) the New Warrants, with an estimated fair value of $ 33,000 . Changes in estimated fair value of these financial instruments from initial recognition to December 31, 2022 were recorded in other income (expense), net. See Note 22 for additional details on how the fair value of all TerrAscend financial instruments are calculated on a recurring basis. The loss of $ 5,094 resulting from the difference, on December 9, 2022, between the carrying amounts of the derecognized financial instruments and the fair value of the financial assets received, was also recorded in other income (expense), net. See Note 3 for information regarding the Reorganization. Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA holds certain U.S. cannabis investments pr eviously held by the Company, including the aforementioned direct and indirect interests in the capital of TerrAscend. Jetty On May 17, 2022, the Company and Jetty entered into definitive agreements (the “Jetty Agreements”) providing the Company with the right to acquire up to 100 % of the outstanding equity interests in Jetty (i) upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana, or to remove the regulation of such activities from the federal laws of the United States; or (ii) an earlier date at the Company’s sole discretion (the “Jetty Triggering Event”). The Jetty Agreements are structured as two separate option agreements whereby the Company has the right to acquire up to 100 % of the equity interests in Jetty. As consideration for entering into the Jetty Agreements, the Company (i) made an upfront cash payment in the amount of $ 29,226 (US$ 22,911 ), and (ii) issued 8,426,539 common shares with a fair value on closing of $ 59,123 (US$ 45,928 ), for total consideration of $ 88,349 (collectively, the “Upfront Payment”). The first option agreement is exercisable in two tranches, with the first tranche providing the Company with the option to acquire 52.78 % of Jetty’s equity interests, exercisable following the occurrence of the Jetty Triggering Event. The second tranche provides the Company with the option to acquire 25 % of Jetty’s equity interests for their fair market value, subject to certain adjustments. Additionally, the Company expects to make deferred payments (the “Deferred Payments”) computed based on a pre-determined contractual formula. The second option agreement provides the Company with the option to acquire 22.22 % of Jetty’s equity interests, exercisable following the occurrence of the Jetty Triggering Event. Upon initial recognition, the Company estimated the fair value of the Jetty financial instrument to be $ 90,120 , consisting of (i) the Upfront Payment as noted above; and (ii) the present value of the estimated Deferred Payments. At December 31, 2022, the estimated fair value of the Jetty financial instruments was $ 85,390 , with the change in estimated fair value from initial recognition recorded in other income (expense), net. See Note 22 for additional details on how the fair value of the Jetty financial instruments is calculated on a recurring basis. See Note 3 for information regarding the Reorganization. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by the Company, which is expected to enable Canopy USA, following, among other things, the Meeting and the exercise of the Acreage Option, including the issuance of the Fixed Shares to Canopy USA, to consummate the acquisitions of Acreage, Wana, and Jetty. Until such time as the Company or Canopy USA (as applicable) elects to exercise its rights to acquire Jetty and the Company converts the Non-Voting Shares into Canopy USA Common Shares, the Company will have no direct or indirect economic or voting interests in Jetty, the Company will not directly or indirectly control Jetty, and the Company and Jetty will continue to operate independently of one another. Acreage-Related Agreements Tax Receivable Agreement On October 24, 2022, the Company and Canopy USA entered into a third amendment to the tax receivable agreement (the "Amended TRA") with, among others, certain current or former unitholders (the "Holders") of High Street Capital Partners, LLC, a subsidiary of Acreage ("HSCP"), pursuant to HSCP's amended tax receivable agreement (the "TRA") and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a fair value of US$ 30,441 to certain Holders as consideration for the assignment of such Holder's rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA. In connection with the foregoing, the Company issued 5,648,927 common shares with a value of $ 20,630 (US$ 15,220 ) to certain Holders on November 4, 2022 as the first installment under the Amended TRA with the second payment of approximately US$ 15,220 in common shares of the Company to occur on the earlier of: (a) the second business day following the date on which the shareholders of Acreage approve the Floating Share Arrangement; or (b) April 24, 2023. Accordingly, as the second payment pursuant to the Amended TRA is not contingent upon any condition, a liability has been recorded in the amount of $ 20,630 (see Note 16). The aggregate amount of $ 41,491 paid, or to be paid, by the Company in common shares in relation to the assignment of rights in favor of Canopy USA in accordance with the Amended TRA represents a financial instrument that has been recorded at cost upon initial recognition. The Company, on behalf of Canopy USA, also agreed to issue common shares of the Company with a value of approximately US$ 19,559 to certain eligible participants pursuant to HSCP’s existing tax receivable bonus plans to be issued immediately prior to completion of the Floating Share Arrangement. No accounting recognition was given to this payment in the three months ended December 31, 2022 as such payment is contingent upon the completion of the Floating Share Arrangement or, if the Floating Share Arrangement is not completed, upon the closing of the acquisition of the Fixed Shares under the Existing Acreage Arrangement Agreement. Acreage Debt Option Premium On November 15, 2022, a wholly-owned subsidiary of Canopy Growth (the "Acreage Debt Optionholder") and Acreage's existing lenders (the "Lenders") entered into an option agreement, which superseded the letter agreement dated October 24, 2022 between the parties, pursuant to which the Acreage Debt Optionholder was granted the right to purchase the outstanding principal, including all accrued and unpaid interest thereon, of Acreage’s debt, being an amount up to US$ 150,000 (the "Acreage Debt") from the Lenders in exchange for an option premium payment of $ 38,048 (US$ 28,500 ) (the "Option Premium"), which was deposited into an escrow account on November 17, 2022. The Acreage Debt Optionholder has the right to exercise the option at its discretion, and if the option is exercised, the Option Premium will be used to reduce the purchase price to be paid for the outstanding Acreage Debt. In the event that Acreage repays the Acreage Debt on or prior to maturity, the Option Premium will be returned to the Acreage Debt Optionholder. In the event that Acreage defaults on the Acreage Debt and the Acreage Debt Optionholder does not exercise its option to acquire the Acreage Debt, the Option Premium will be released to the Lenders. The Option Premium represents a financial instrument that has been recorded at cost upon initial recognition.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Dec. 31, 2022
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	11 . PROPERTY, PLANT AND EQUIPMENT The components of property, plant and equipment are as follows: December 31, March 31, 2022 2022 Buildings and greenhouses $ 752,177 $ 766,931 Production and warehouse equipment 140,975 159,314 Leasehold improvements 24,323 69,304 Office and lab equipment 24,263 29,879 Computer equipment 18,060 22,293 Land 17,395 18,917 Right-of-use-assets Buildings and greenhouses 74,153 89,228 Production and warehouse equipment 27 55 Assets in process 12,712 19,771 1,064,085 1,175,692 Less: Accumulated depreciation ( 190,056 ) ( 232,912 ) $ 874,029 $ 942,780 Depreciation expense included in cost of goods sold for the three and nine months ended December 31, 2022 is $ 12,033 and $ 34,423 , respectively (three and nine months ended December 31, 2021 – $ 13,813 and $ 38,663 , respectively). Depreciation expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2022 is $ 1,544 and $ 8,762 , respectively (three and nine months ended December 31, 2021 – $ 5,546 and $ 17,804 , respectively).

Intangible Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2022
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets	12 . INTANGIBLE ASSETS The components of intangible assets are as follows: December 31, 2022 March 31, 2022 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 141,488 $ 89,758 $ 138,170 $ 97,638 Distribution channel 72,799 22,045 72,642 24,834 Operating licenses 24,400 19,762 24,400 22,052 Software and domain names 36,464 15,221 29,822 14,206 Brands 5,620 3,128 5,547 3,680 Amortizable intangibles in process 842 842 5,476 5,476 Total $ 281,613 $ 150,756 $ 276,057 $ 167,886 Indefinite lived intangible assets Acquired brands $ 62,774 $ 74,809 Operating licenses - 10,000 Total intangible assets $ 213,530 $ 252,695 Amortization expense included in cost of goods sold for the three and nine months ended December 31, 2022 is $ 16 and $ 45 , respectively (three and nine months ended December 31, 2021 – $ 19 and $ 62 , respectively). Amortization expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2022 is $ 7,009 and $ 20,516 , respectively (three and nine months ended December 31, 2021 – $ 10,639 and $ 27,400 , respectively).

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	13 . GOODWILL The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 105,323 Disposal of consolidated entities ( 58,786 ) Impairment losses ( 40,748 ) Foreign currency translation adjustments ( 28,640 ) Balance, March 31, 2022 $ 1,866,503 Disposal of consolidated entities ( 227 ) Impairment losses ( 1,727,679 ) Foreign currency translation adjustments 3,479 Balance, December 31, 2022 $ 142,076 As a result of the continued decline in the price of the Company’s common shares in the three months ended June 30, 2022, the Company determined there to be an indicator of impairment for the cannabis operations reporting unit in the global cannabis segment, which was a reportable segment in the three months ended June 30, 2022. As a result, the Company performed a quantitative interim goodwill impairment assessment for the cannabis operations reporting unit as of June 30, 2022. The Company concluded that the carrying value of the cannabis operations reporting unit was higher than its estimated fair value, and a goodwill impairment loss totaling $ 1,725,368 was recognized in the three months ended June 30, 2022, representing the entirety of the goodwill assigned to the cannabis operations reporting unit. The estimated fair value of the cannabis operations reporting unit was determined using the market valuation method, which is consistent with the methodology used by the Company for its annual impairment test conducted at March 31, 2022. The most significant assumptions used in applying this method were (i) the price of the Company’s common shares; and (ii) the estimated control premium associated with ownership of the Company’s common shares. While the Company changed its reportable segments in the three months ended September 30, 2022 (refer to Note 30), there were no changes to the composition of the Company's reporting units to which goodwill remains assigned at September 30, 2022. In the three months ended September 30, 2022, the Company determined there to be indicators of impairment for one of its other reporting units as slower growth rates resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation. As a result, the Company performed a quantitative interim goodwill impairment test for the reporting unit as of September 30, 2022 and concluded that the carrying value of the reporting unit was higher than its estimated fair value, as determined using the income valuation method. The Company recognized a goodwill impairment loss totaling $ 2,311 in the three months ended September 30, 2022, representing the entirety of the goodwill assigned to the reporting unit. For the remaining reporting units, the Company does not believe that an event occurred or circumstances changed during the three months ended September 30, 2022 that would, more likely than not, reduce the fair value of these reporting units below their carrying value. Therefore, the Company concluded that the quantitative goodwill impairment assessment was not required for the remaining reporting units at September 30, 2022. The Company does not believe that an event occurred or circumstances changed during the three months ended December 31, 2022 that would, more likely than not, reduce the fair values of the remaining reporting units below their carrying values. Therefore, the Company concluded that the quantitative goodwill impairment assessment was not required for the remaining reporting units at December 31, 2022. The carrying value of goodwill associated with all other reporting units was $ 142,076 at December 31, 2022. The Company is required to perform its next annual goodwill impairment analysis on March 31, 2023, or earlier should there be an event that occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.

Other Accrued Expenses and Liab

Other Accrued Expenses and Liabilities	9 Months Ended
	Dec. 31, 2022
Accounts Payable And Accrued Liabilities Current [Abstract]
Other Accrued Expenses and Liabilities	14 . OTHER ACCRUED EXPENSES AND LIABILITIES The components of other accrued expenses and liabilities are as follows: December 31, March 31, 2022 2022 Employee compensation $ 29,213 $ 24,873 Inventory 951 10,096 Professional fees 6,891 7,640 Taxes and government fees 8,541 7,144 Other 30,389 25,525 $ 75,985 $ 75,278

Debt

Debt	9 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	15 . DEBT The components of debt are as follows: December 31, March 31, Maturity Date 2022 2022 Unsecured senior notes at 4.25 % interest with July 15, 2023 Principal amount $ 337,380 $ 600,000 Accrued interest 6,731 5,958 Non-credit risk fair value adjustment 19,062 7,140 Credit risk fair value adjustment ( 37,618 ) ( 49,140 ) 325,555 563,958 Convertible debentures September 10, 2025 30,867 32,858 Accretion debentures September 10, 2025 8,506 7,720 Credit facility March 18, 2026 838,407 893,647 Other revolving debt facility, loan, and financings 2,266 2,808 1,205,601 1,500,991 Less: current portion ( 455,483 ) ( 9,296 ) Long-term portion $ 750,118 $ 1,491,695 Credit Facility On March 18, 2021, the Company entered into the Credit Agreement providing for a five-year , first lien senior secured term loan facility in an aggregate principal amount of US$ 750,000 (the “Credit Facility”). The Company had the ability to obtain up to an additional US$ 500,000 of incremental senior secured debt pursuant to the Credit Agreement. As described in Note 3 , in connection with the balance sheet actions completed as part of the creation of Canopy USA, the Company entered into agreements with certain of its lenders under the Credit Agreement to complete the Paydown, which will result in the Company tendering US$ 187,500 of principal amount outstanding thereunder at a discounted price of US$ 930 per US$ 1,000 or US$ 174,375 in the aggregate. The first payment in the amount of $ 117,528 (US $ 87,852 ), representing an aggregate principal payment amount of $ 126,324 (US $ 94,427 ) was made on November 10, 2022, and the second payment pursuant to the Paydown is to be made no later than April 17, 2023. The Company also agreed to the Credit Agreement Amendments which, among other things, resulted in: (i) reductions to the minimum Liquidity (as defined in the Credit Agreement) covenant to US$ 100,000 , which is to be further reduced as payments are made in accordance with the Paydown; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$ 100,000 ; and (iv) the elimination of the additional US$ 500,000 incremental term loan facility. The Credit Facility has no principal payments, matures on March 18, 2026 , has a coupon of LIBOR plus 8.50 % and is subject to a LIBOR floor of 1.00 %. In the event that LIBOR can no longer be adequately ascertained or is no longer available, an alternative rate as permitted under the Credit Agreement will be used. The Company’s obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of these assets, including material real property, of the borrowers and each of the guarantors. The Credit Agreement contains representations and warranties, and affirmative and negative covenants, including a financial covenant requiring minimum liquidity of US$ 200,000 at the end of each fiscal quarter; however, as noted above, as a result of the Credit Agreement Amendments, such minimum liquidity covenant has been reduced to US$ 100,000 , which is to be reduced as payments are made in accordance with the Paydown. The proceeds from the Credit Facility were $ 893,160 , and the carrying amount is reflected net of financing costs. Unsecured Senior Notes On June 20, 2018, the Company issued the Notes with an aggregate principal amount of $ 600,000 . The Notes bear interest at a rate of 4.25 % per annum, payable semi-annually on January 15th and July 15th of each year commencing from January 15, 2019 . The Notes will mature on July 15, 2023 . The Notes are subordinated in right of payment to any existing and future senior indebtedness. The Notes will rank senior in right of payment to any future subordinated borrowings. The Notes are effectively junior to any secured indebtedness and the Notes are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. On June 29, 2022 and June 30, 2022, the Company entered into privately negotiated exchange agreements (the “Exchange Agreements”) with a limited number of holders of the Notes including Greenstar (collectively, the “Noteholders”). Pursuant to the Exchange Agreements, the Company agreed to acquire and cancel approximately $ 262,620 of aggregate principal amount of the Notes from the Noteholders (the “Exchange Transaction”) for an aggregate purchase price (excluding $ 5,383 paid to the Noteholders in cash for accrued and unpaid interest) of $ 259,994 (the “Purchase Price”), which was payable in the Company’s common shares. On the initial closings, 35,662,420 common shares were to be issued to the Noteholders, other than Greenstar, based on a price equal to US$ 3.50 per common share, which was the closing price of the common shares on the Nasdaq Global Select Market on June 29, 2022. The Company satisfied the Purchase Price as follows: • On June 30, 2022, 14,069,353 common shares were issued to Noteholders, representing the Company’s acquisition and cancellation of an aggregate principal amount of Notes of $ 63,098 , which were recorded at a fair value of $ 50,866 . • In July 2022, 21,593,067 common shares were issued to Noteholders, representing an aggregate principal amount of Notes of $ 99,522 , which were recorded at a fair value of $ 76,424 upon acquisition and cancellation. • On the final closing on July 18, 2022 (the “Final Closing”), 11,896,536 common shares were issued to Noteholders other than Greenstar, based on the volume-weighted average trading price of the common shares on the Nasdaq Global Select Market for the 10 consecutive trading days beginning on, and including, June 30, 2022, being US$ 2.6245 (the “Averaging Price”). • In addition, on the Final Closing on July 18, 2022, 29,245,456 common shares were issued to Greenstar based on a price per common share equal to the Averaging Price. Pursuant to the Exchange Transaction, the Company agreed to acquire and cancel $ 100,000 in aggregate principal amount, which was recorded at a fair value of $ 98,078 upon acquisition and cancellation. Prior to the completion of the Exchange Transaction, Greenstar held $ 200,000 in aggregate principal amount of the Notes. In total, 62,735,059 common shares were issued in July 2022, representing the Company's acquisition and cancellation of an aggregate principal amount of Notes of $ 199,522 , and a total of 76,804,412 common shares were issued in June and July 2022, representing the Company's acquisition and cancellation of an aggregate principal amount of Notes of $ 262,620 . The Notes were issued pursuant to an indenture dated June 20, 2018, as supplemented on April 30, 2019 and June 29, 2022 (collectively, the “Indenture”). As a result of a supplement to the Indenture dated June 29, 2022 (the “Second Supplemental Indenture”), the Company irrevocably surrendered its right to settle the conversion of any Note with its common shares. As a result, all conversions of Notes following the execution of the Second Supplemental Indenture will be settled entirely in cash. The Noteholders may redeem the Notes at their option at any time from January 15, 2023 to the maturity date for cash. In addition, the holder has the right to redeem the Notes from September 30, 2018 to January 15, 2023, if (i) the market price of the Company’s common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130 % of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $ 1 principal amount of the Notes for each trading day in the Measurement Period was less than 98 % of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by the CBI and its affiliates (together, the “CBI Group”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith . Under the terms of the Indenture, if a Fundamental Change occurs and a holder elects to redeem its Notes from and including on the date of the Fundamental Change up to, and including, the business day immediately prior to the Fundamental Change repurchase date, the Company, upon conversion by the holder, will settle in cash, subject to certain circumstances. Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law. On or after July 20, 2021 , the Company can redeem for cash, subject to certain conditions, any or all of the Notes, at its option, if the last reported sales price of the Company’s common shares for at least 20 trading days during any 30 consecutive trading day period ending within 5 trading days immediately preceding the date on which the Company provides notice of redemption exceeds 130 % of the initial conversion price on each applicable trading day. The Company may also redeem the Notes, if certain tax laws related to Canadian withholding tax change subject to certain further conditions. The redemption of Notes in either case shall be at a redemption price equal to 100 % of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. The Notes were initially recognized at fair value on the balance sheet and continue to be recorded at fair value. All subsequent changes in fair value, excluding the impact of the change in fair value related to the Company’s own credit risk, are recorded in other income (expense), net. The changes in fair value related to the Company’s own credit risk are recorded through other comprehensive income (loss). During the three and nine months ended December 31, 2022 , the Company acquired and cancelled an aggregate principal amount of Notes of $ nil and $ 262,620 , respectively, which resulted in a release of accumulated other comprehensive income into other income (expense), net for the three and nine months ended December 31, 2022 of $nil and $ 44,370 , respectively. The related tax impact of $ nil and $ 14,862 for the three and nine months ended December 31, 2022, respectively, associated with the aggregate principal amount acquired and cancelled was also released from accumulated other comprehensive income into income tax expense. Refer to Note 20. In connection with the Exchange Transaction, in the three months ended June 30, 2022, the Company recognized a derivative liability of $ 26,594 in connection with the incremental common shares that were potentially issuable to Noteholders, other than Greenstar, as at June 30, 2022 at the Averaging Price on the Final Closing. The derivative liability, and associated fair value changes in the three and nine months ended December 31, 2022 , were recorded through other income (expense), net. The derivative liability with a fair value of $ 39,896 was derecognized upon Final Closing on July 18, 2022. The overall change in fair value of the Notes during the three and nine months ended December 31, 2022, was an increase of $ 4,427 and a decrease of $ 238,403 , respectively (three and nine months ended December 31, 2021, a decrease of $ 16,806 and a decrease of $ 120,372 , respectively), which included contractual interest of $ 3,583 and $ 13,370 , respectively (three and nine months ended December 31, 2021 – $ 6,444 and $ 19,128 , respectively) and principal redemption of $ nil and $ 262,620 , respectively. Upon redemption, the principal redeemed during the three and nine months ended December 31, 2022 had a fair value of $ nil and $ 225,369 , respectively. Refer to Note 22 for additional details on how the fair value of the Notes is calculated. Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, The Supreme Cannabis Company, Inc. (“Supreme Cannabis”) entered into an indenture with Computershare Trust Company of Canada (the “Trustee”) pursuant to which Supreme Cannabis issued 6.0 % senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of $ 100,000 . On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among other things: (i) the cancellation of $ 63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8 % per annum; (iii) the extension of the maturity date to September 10, 2025 ; and (iv) a reduction in the conversion price to $ 0.285 . In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at $nil and accretes at a rate of 11.06 % per annum based on the remaining principal amount of the Supreme Debentures of $ 36,500 to a maximum of $ 13,500 , compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into the common shares of Supreme Cannabis (the “Supreme Shares”). The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0 % per month over the 24 months prior to maturity. As a result of the completion of an arrangement, on June 22, 2021 by the Company and Supreme Cannabis, pursuant to which the Company acquired 100 % of the issued and outstanding Supreme Shares (the “Supreme Arrangement”), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures are not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Convertible Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full.

Other Liabilities

Other Liabilities	9 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	. OTHER LIABILITIES The components of other liabilities are as follows: As at December 31, 2022 As at March 31, 2022 Current Long-term Total Current Long-term Total Lease liabilities $ 35,537 $ 83,167 $ 118,704 $ 38,035 $ 101,125 $ 139,160 Acquisition consideration 7,908 47,169 55,077 4,020 77,834 81,854 Refund liability 2,937 - 2,937 3,437 - 3,437 Settlement liabilities and 37,752 11,555 49,307 18,562 11,090 29,652 $ 84,134 $ 141,891 $ 226,025 $ 64,054 $ 190,049 $ 254,103 The estimated deferred payments associated with the Wana financial instrument within acquisition consideration and other investment related liabilities at December 31, 2022 is $ 39,307 (March 31, 2022 – $ 70,066 ). In connection with the second installment payable by the Company, on behalf of Canopy USA, pursuant to the Amended TRA, as described in Note 10 , a liability has been recorded at December 31, 2022 in the amount of $ 20,630 in settlement liabilities and other.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interest	9 Months Ended
	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Redeemable Noncontrolling Interest	17 . REDEEMABLE NONCONTROLLING INTEREST The net changes in the redeemable noncontrolling interests are as follows: Vert BioSteel Total As at March 31, 2022 $ 1,000 $ 35,200 $ 36,200 Net income (loss) attributable to redeemable noncontrolling interest 508 ( 18,316 ) ( 17,808 ) Adjustments to redemption amount ( 508 ) 20,874 20,366 Redemption of redeemable noncontrolling interest - ( 27,350 ) ( 27,350 ) As at December 31, 2022 $ 1,000 $ 10,408 $ 11,408 Vert BioSteel Total As at March 31, 2021 $ 11,500 $ 123,800 $ 135,300 Net income (loss) attributable to redeemable noncontrolling interest ( 2,401 ) ( 10,699 ) ( 13,100 ) Adjustments to redemption amount 2,401 ( 50,792 ) ( 48,391 ) Redemption of redeemable noncontrolling interest ( 5,109 ) ( 5,109 ) As at December 31, 2021 $ 11,500 $ 57,200 $ 68,700

Share Capital

Share Capital	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Share Capital	18 . SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares. (i) Equity financings There were no equity financings during the nine months ended December 31, 2022 (nine months ended December 31, 2021 - no ne). (ii) Other issuances of common shares During the nine months ended December 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Jetty Agreements 8,426,539 $ 59,013 $ - HSCP Holders pursuant to Amended TRA 5,648,927 20,630 - Completion of acquisition milestones 222,421 1,379 ( 1,379 ) Other issuances 237,802 1,209 ( 353 ) Total 14,535,689 $ 82,231 $ ( 1,732 ) For the three and nine months ended December 31, 2022 , the Company also issued 8,692,128 common shares with a value of $ 26,506 relating to its redemption of the redeemable noncontrolling interest in BioSteel. The redemption increases the Company's interest in BioSteel from 78.6 % to 90.3 %. During the nine months ended December 31, 2021 , the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 ( 29,721 ) Other issuances 351,252 6,630 ( 405 ) Total 10,659,937 $ 296,574 $ ( 30,126 ) (iii) Warrants Number of Average Warrant Balance outstanding at March 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 Expiry of warrants - - - Balance outstanding at December 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 1 This balance excludes the Tranche C Warrants (as defined below), which represent a derivative liability and have nominal value. See Note 29. Number of Average Warrant Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants ( 145,831 ) 32.61 - Balance outstanding at December 31, 2021 1 128,193,047 $ 58.04 $ 2,581,788 1 This balance excludes the Tranche C Warrants, which represent a derivative liability and have nominal value. See Note 29 .

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	19 . SHARE-BASED COMPENSATION CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN Canopy Growth's eligible employees participate in a share-based compensation plan as noted below. On September 21, 2020, the Company’s shareholders approved amendments to the Company’s Amended and Restated Omnibus Incentive Plan (as amended and restated, the “Omnibus Plan”) pursuant to which the Company can issue share-based long-term incentives. The Omnibus Plan approved by the shareholders extended the maximum term of each Option (as defined below) to be granted by the Company to ten years from the date of grant rather than six years from the date of grant. On May 27, 2021, the Board of Directors of the Company (the "Board") approved certain amendments to the Omnibus Plan in order to reduce the maximum number of shares available for issuance under the Omnibus Plan from 15 % of the issued and outstanding shares to 10 % of the issued and outstanding shares from time to time less the number of shares issuable pursuant to other security-based compensation arrangements of the Company. All directors, officers, employees and independent contractors of the Company are eligible to receive awards of common share purchase options (“Options”), restricted share units (“RSUs”), performance share units (“PSUs”), deferred share units, stock appreciation rights, performance awards, or other shares-based awards (collectively, the “Awards”) under the Omnibus Plan. The maximum number of common shares reserved for Awards is 49,489,139 at December 31, 2022. As of December 31, 2022, the only Awards issued have been Options, RSUs and PSUs under the Omnibus Plan. The Omnibus Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Board (the “CGC&N Committee”) which establishes exercise prices, at not less than the market price at the date of grant, and expiry dates. Awards under the Omnibus Plan generally vest in increments with 1/3 vesting on each of the first, second and third anniversaries from the date of grant, with expiry dates set at ten years from issuance, subject to the discretion of the CGC&N Committee pursuant to the Omnibus Plan to provide for an alternative expiry date or vesting period in an award agreement for the grant of Awards, subject to limits contained in the Omnibus Plan. Under the Company’s Employee Share Purchase Plan (the “Purchase Plan”) the aggregate number of common shares that may be issued is 600,000 , and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 300,000 . For the three and nine months ended December 31, 2022, nil and 237,802 common shares were issued under the Purchase Plan (three and nine months ended December 31, 2021 – nil and 61,103 ). The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2022: Options Weighted Balance outstanding at March 31, 2022 16,782,962 $ 33.89 Options granted 4,651,176 4.94 Options exercised ( 76,929 ) 3.41 Options forfeited ( 6,058,172 ) 29.37 Balance outstanding at December 31, 2022 15,299,037 $ 27.07 The following is a summary of the Options outstanding as at December 31, 2022: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices December 31, 2022 (years) December 31, 2022 (years) $ 0.06 - $ 24.62 6,083,908 4.83 1,369,076 2.77 $ 24.63 - $ 33.53 3,281,232 2.58 2,033,996 2.24 $ 33.54 - $ 36.80 1,569,568 1.94 1,569,568 1.94 $ 36.81 - $ 42.84 1,800,926 2.05 1,794,649 2.02 $ 42.85 - $ 67.64 2,563,403 2.10 2,563,403 2.10 15,299,037 3.27 9,330,692 2.19 At December 31, 2022, the weighted average exercise price of Options outstanding and Options exercisable was $ 27.07 and $ 37.46 , respectively (March 31, 2022 – $ 33.89 and $ 38.33 , respectively). The Company recorded $ 1,790 and $ 5,175 in share-based compensation expense related to Options and Purchase Plan shares issued to employees and contractors for the three and nine months ended December 31, 2022, respectively (three and nine months ended December 31, 2021 – $ 3,696 and $ 22,038 , respectively). The share-based compensation expense for the nine months ended December 31, 2022, includes an amount related to 1,078,748 Options being provided in exchange for services which are subject to performance conditions (for the nine months ended December 31, 2021 – 1,559,413 ). During the three months ended June 30, 2021, the Company issued replacement options to employees in relation to the acquisition of Supreme Cannabis and recorded share-based compensation expense of $ 823 . The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2022 and 2021, on their measurement date by applying the following assumptions: December 31, December 31, 2022 2021 Risk-free interest rate 3.47 % 1.21 % Expected life of options (years) 3 - 5 3 - 5 Expected volatility 82 % 75 % Expected forfeiture rate 20 % 18 % Expected dividend yield nil nil Black-Scholes value of each option $ 3.34 $ 7.55 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options. During the nine months ended December 31, 2022, 76,929 Options were exercised ranging in price from $ 0.06 to $ 8.18 for gross proceeds of $ 271 (for the nine months ended December 31, 2021 – 421,476 Options were exercised ranging in price from $ 0.06 to $ 36.34 for gross proceeds of $ 5,455 ). For the three and nine months ended December 31, 2022, the Company recorded $ 4,265 and $ 15,718 , respectively, in share-based compensation expense related to RSUs and PSUs (for the three and nine months ended December 31, 2021 – $ 1,950 and $ 7,935 , respectively). The following is a summary of the changes in the Company’s RSUs and PSUs during the nine months ended December 31, 2022: Number of RSUs Balance outstanding at March 31, 2022 3,477,292 RSUs and PSUs granted 3,128,198 RSUs and PSUs released ( 359,628 ) RSUs and PSUs cancelled and forfeited ( 1,925,026 ) Balance outstanding at December 31, 2022 4,320,836 During the three and nine months ended December 31, 2022, the Company recorded $ nil in share-based compensation expense related to acquisition milestones (for the three and nine months ended December 31, 2021 – $ 971 and $ 4,376 , respectively). During the three and nine months ended December 31, 2022, 222,421 common shares were released on completion of acquisition milestones (during the three and nine months ended December 31, 2021 – 419,884 and 1,295,285 , respectively). At December 31, 2022, there were up to 125,489 common shares to be issued on the completion of acquisition and asset purchase milestones. In certain cases, the number of common shares to be issued is based on the volume weighted average share price at the time the milestones are met. The number of common shares has been estimated assuming the milestones were met at December 31, 2022. BioSteel share-based payments On October 1, 2019, the Company purchased 72 % of the outstanding shares of BioSteel Sports Nutrition Inc. (“BioSteel”). BioSteel has a stock option plan under which non-transferable options to purchase common shares of BioSteel may be granted to directors, officers, employees, or independent contractors of the BioSteel. As at December 31, 2022, BioSteel had 924,719 (March 31, 2022 – 1,565,300 ) options outstanding which vest in equal tranches over a 5 -year period. In determining the amount of share-based compensation related to these options, BioSteel used the Black-Scholes option pricing model to establish the fair value of options on their measurement date. The Company recorded $ 373 and $ 832 of share-based compensation expense related to the BioSteel options during the three and nine months ended December 31, 2022, respectively, (three and nine months ended December 31, 2021 – $ 160 and $ 684 , respectively).

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	20 . ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2022 $ ( 57,468 ) $ 15,186 $ ( 42,282 ) Settlement of unsecured senior notes, net of tax - ( 29,507 ) ( 29,507 ) Other comprehensive income 24,694 32,847 57,541 As at December 31, 2022 $ ( 32,774 ) $ 18,526 $ ( 14,248 ) Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2021 $ ( 28,246 ) $ ( 5,994 ) $ ( 34,240 ) Other comprehensive (loss) income ( 18,767 ) 26,280 7,513 As at December 31, 2021 $ ( 47,013 ) $ 20,286 $ ( 26,727 )

Noncontrolling Interests

Noncontrolling Interests	9 Months Ended
	Dec. 31, 2022
Noncontrolling Interest [Abstract]
Noncontrolling Interests	21 . NONCONTROLLING INTERESTS The net change in the noncontrolling interests is as follows: Vert BioSteel Other Total As at March 31, 2022 $ - $ 2,497 $ 1,844 $ 4,341 Comprehensive income (loss) 508 ( 18,316 ) ( 1,844 ) ( 19,652 ) Net (income) loss attributable to redeemable noncontrolling ( 508 ) 18,316 - 17,808 Share-based compensation - 495 - 495 Ownership changes - ( 1,552 ) 1,356 ( 196 ) As at December 31, 2022 $ - $ 1,440 $ 1,356 $ 2,796 Vert BioSteel Other non- Total As at March 31, 2021 $ - $ 1,658 $ 3,051 $ 4,709 Comprehensive loss ( 2,401 ) ( 10,699 ) ( 1,207 ) ( 14,307 ) Net loss attributable to redeemable noncontrolling interest 2,401 10,699 - 13,100 Share-based compensation - 684 - 684 As at December 31, 2021 $ - $ 2,342 $ 1,844 $ 4,186

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	22 . FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: • Level 1 – defined as observable inputs such as quoted prices in active markets; • Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value measurement is categorized in its entirety by reference to its lowest level of significant input. The Company records cash, accounts receivable, interest receivable and accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. The Company determines the fair value of these items using Level 3 inputs, as described in the related sections below. The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2022 Assets: Short-term investments $ 191,119 $ - $ - $ 191,119 Restricted short-term investments 12,932 - - 12,932 Other financial assets 251 - 508,813 509,064 Liabilities: Unsecured senior notes - 325,555 - 325,555 Warrant derivative liability - - 668 668 Other liabilities - - 43,102 43,102 March 31, 2022 Assets: Short-term investments $ 595,651 $ - $ - $ 595,651 Restricted short-term investments 12,216 - - 12,216 Other financial assets 490 - 787,816 788,306 Liabilities: Unsecured senior notes - 563,958 - 563,958 Liability arising from Acreage Arrangement - - 47,000 47,000 Warrant derivative liability - - 26,920 26,920 Other liabilities - - 70,066 70,066 The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Unsecured senior notes Senior note pricing model Quoted prices in over-the-counter broker market The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - December 2022 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Wana financial instrument - Call Discounted cash flow Expected future Wana cash flows Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value Option Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana equity Increase or decrease in volatility will result in an increase or decrease in fair value Jetty financial instrument - Discounted cash flow Expected future Jetty cash flows Increase or decrease in expected future Jetty cash flows will result in an increase or decrease in fair value Call Option Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Jetty financial instrument - Deferred Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Payments Volatility of Jetty equity and revenue Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Expected future BioSteel cash flows Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value Vert Mirabel redeemable Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value noncontrolling interest Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Revenue

Revenue	9 Months Ended
	Dec. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue	23 . REVENUE Revenue is disaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Canada cannabis Canadian adult-use cannabis Business-to-business 1 $ 21,522 $ 33,282 $ 73,379 $ 117,902 Business-to-consumer 11,036 14,477 36,243 48,473 32,558 47,759 109,622 166,375 Canadian medical cannabis 2 14,059 12,919 41,714 39,504 $ 46,617 $ 60,678 $ 151,336 $ 205,879 Rest-of-world cannabis C 3 - 9,675 - 33,005 Other rest-of-world cannabis 5,846 12,624 30,179 32,357 $ 5,846 $ 22,299 $ 30,179 $ 65,362 Storz & Bickel $ 20,214 $ 25,205 $ 49,351 $ 63,786 BioSteel $ 16,363 $ 16,974 $ 64,173 $ 31,147 This Works $ 8,289 $ 10,730 $ 20,677 $ 26,308 Other 3,884 5,086 13,475 16,073 Net revenue $ 101,213 $ 140,972 $ 329,191 $ 408,555 1 Canadian adult-use business-to-business net revenue during the three and nine months ended December 31, 2022 reflects excise taxes of $ 10,797 and $ 33,754 , respectively (three and nine months ended December 31, 2021 – $ 12,754 and $ 43,501 , respectively). 2 Canadian medical cannabis net revenue for the three and nine months ended December 31, 2022 reflects excise taxes of $ 1,339 and $ 3,625 , respectively (three and nine months ended December 31, 2021 – $ 1,298 and $ 4,039 , respectively). The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $ 8,869 and $ 15,345 for the three and nine months ended December 31, 2022, respectively (three and nine months ended December 31, 2021 – $ 3,726 and $ 12,375 , respectively). As of December 31, 2022, the liability for estimated returns and price adjustments was $ 2,937 (March 31, 2022 – $ 3,437 ).

Other Income (Expense), Net

Other Income (Expense), Net	9 Months Ended
	Dec. 31, 2022
Other Income And Expenses [Abstract]
Other Income (Expense), Net	. OTHER INCOME (EXPENSE), NET Other income (expense), net is disaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Fair value changes on other financial assets $ ( 95,815 ) $ ( 68,666 ) $ ( 396,755 ) $ ( 263,946 ) Fair value changes on liability arising from Acreage - 59,000 47,000 497,000 Fair value changes on unsecured senior notes ( 8,964 ) 606 ( 32,365 ) 81,342 Fair value changes on warrant derivative liability 23 67,282 26,252 578,084 Fair value changes on acquisition related contingent 1,762 712 25,902 544 Gain (loss) and charges related to settlement of debt 8,912 - 4,224 - Interest income 7,048 1,575 15,922 6,977 Interest expense ( 33,288 ) ( 26,408 ) ( 90,660 ) ( 77,618 ) Foreign currency gain (loss) 2,966 990 ( 8,828 ) 2,902 Gain (loss) on disposal/acquisition of consolidated entity 4,142 - 6,223 ( 1,653 ) Other income (expense), net ( 126 ) ( 809 ) ( 3,677 ) ( 12,863 ) $ ( 113,340 ) $ 34,282 $ ( 406,762 ) $ 810,769

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	25 . INCOME TAXES There have been no material changes to income tax matters in connection with normal course operations during the nine months ended December 31, 2022. The Company is subject to income tax in numerous jurisdictions with varying income tax rates. During the most recent period ended and the fiscal year to date, there were no material changes to the statutory income tax rates in the taxing jurisdictions where the majority of the Company’s income for tax purposes was earned, or where its temporary differences or losses are expected to be realized or settled. Although statutory income tax rates remain stable, the Company’s effective income tax rate may fluctuate, arising as a result of the Company’s evolving footprint, discrete transactions and other factors that, to the extent material, are disclosed in these financial statements. The Company continues to believe that the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the reporting period in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the reporting period during which such determination is made.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	26 . EARNINGS (LOSS) PER SHARE Basic and diluted earnings (loss) per share are calculated using the following numerators and denominators: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Basic (loss) earnings per share computation Net (loss) income attributable to common shareholders of $ ( 261,583 ) $ ( 108,925 ) $ ( 2,566,537 ) $ 272,435 Weighted average number of common shares outstanding 486,112,598 393,818,282 453,237,882 390,423,083 Basic (loss) earnings per share $ ( 0.54 ) $ ( 0.28 ) $ ( 5.66 ) $ 0.70 Diluted (loss) earnings per share computation Net (loss) income used in the computation of basic (loss) $ ( 261,583 ) $ ( 108,925 ) $ ( 2,566,537 ) $ 272,435 Numerator adjustments for diluted (loss) earnings per share: Adjustment to net loss attributable to noncontrolling - - - ( 13,100 ) Removal of fair value changes on unsecured senior notes - - - ( 81,342 ) Net (loss) income used in the computation of diluted (loss) $ ( 261,583 ) $ ( 108,925 ) $ ( 2,566,537 ) $ 177,993 Weighted average number of common shares outstanding 486,112,598 393,818,282 453,237,882 390,423,083 Denominator adjustments for diluted (loss) earnings per Dilutive impact of assumed exercise or conversion of: Unsecured senior notes - - - 12,454,620 Redeemable noncontrolling interest - - - 4,528,898 Stock options - - - 745,700 Other securities - - - 2,834,501 Weighted average number of common shares for 486,112,598 393,818,282 453,237,882 410,986,802 Diluted (loss) earnings per share 1 $ ( 0.54 ) $ ( 0.28 ) $ ( 5.66 ) $ 0.43 1 In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive.

Acquisition

Acquisition	9 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Acquisition	27 . ACQUISITION The following table summarizes the consolidated balance sheet impact at acquisition of the Company's business combination that occurred in the nine months ended December 31, 2022: Verona Manufacturing Facility Property, plant and equipment $ 28,771 Debt and other liabilities ( 2,373 ) Net assets acquired $ 26,398 Consideration paid in cash $ 24,223 Other consideration 2,175 Total consideration $ 26,398 Consideration paid in cash $ 24,223 Less: Cash and cash equivalents acquired - Net cash outflow $ 24,223 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for the acquisition completed in the nine months ended December 31, 2022. Acquisition of Verona Manufacturing Facility On November 8, 2022, the Company, through its affiliate BioSteel, completed the acquisition (the "Verona Acquisition") of a manufacturing facility located in Verona, Virginia (the "Verona Facility") from Flow Beverage Corp. ("Flow"), one of BioSteel's contract manufacturers. Consideration was $ 26,398 (US$ 19,477 ), consisting of cash paid of $ 15,685 (US$ 11,573 ) and $ 8,538 (US$ 6,299 ) related to the repayment of debt and the retirement of certain lease obligations, and $ 2,175 (US$ 1,605 ) in remediation and indemnity holdbacks to be retained by the Company and paid within one year of the closing of the Verona Acquisition. BioSteel and Flow have also entered into a co-manufacturing agreement whereby, in addition to the production of BioSteel-branded sports hydration beverages, BioSteel will produce Flow's portfolio of branded water at the Verona Facility. Due to the timing of the Verona Acquisition, the purchase price allocation for the Verona Acquisition is provisional. The fair value assigned to the consideration paid and net assets acquired is based on management's best estimate using the information currently available and may be revised by the Company as additional information is received.

Retail Divestiture

Retail Divestiture	9 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Retail Divestiture	28 . RETAIL DIVESTITURE The Company entered into the following two agreements to divest its retail business in Canada, which includes the retail stores operating under the Tweed and Tokyo Smoke banners: • An agreement with OEG Retail Cannabis (“ OEGRC”), a prior Canopy Growth licensee partner, pursuant to which OEGRC acquired ownership of 23 of the Company's corporate-owned retail stores in Manitoba, Saskatchewan and Newfoundland and Labrador, as well as all Tokyo Smoke-related intellectual property (the “OEGRC Transaction”). In connection with the OEGRC Transaction, the Tokyo Smoke brand has been transferred to OEGRC and all acquired retail stores branded as Tweed will be rebranded by OEGRC. In addition, the master franchise agreement between the Company and OEGRC, pursuant to which OEGRC licenses the Tokyo Smoke brand in Ontario, was terminated effective on the closing of the OEGRC Transaction. The OEGRC Transaction closed on December 30, 2022. • An agreement (the "FOUR20 Agreement") with 420 Investments Ltd. (“FOUR20”), a licensed cannabis retailer, pursuant to which FOUR20 acquired ownership of five of the Company's corporate-owned retail stores in Alberta (the “FOUR20 Transaction”). Pursuant to the FOUR20 Agreement, the stores will be rebranded under FOUR20's retail banner upon closing of the FOUR20 Transaction. The FOUR20 Transaction closed on October 26, 2022. In the three months ended December 31, 2022, upon closing of the OEGRC Transaction and the FOUR20 Transaction, the Company received a cash paymen t of $ 88 . The Company will also be entitled to deferred consideration of $ 5,500 , and an earn-out payment of $ 6,099 , subject to the achievement of certain revenue targets by the divested retail stores. Following the divestiture of the retail stores pursuant to the OEGRC Transaction and the FOUR20 Transaction, the Company derecognized the assets and liabilities of the associated retail stores from these consolidated financial statements at their carrying amounts on their respective closing dates, as follows: Current assets $ 6,461 Property, plant and equipment 7,990 Other long-term assets 144 Current liabilities ( 9,492 ) Net assets disposed $ 5,103 Consideration received in cash $ 88 Future cash consideration 11,599 Costs to sell ( 2,442 ) Total consideration $ 9,245 Gain on disposal of consolidated entity $ 4,142 The gain calculated on the derecognition of the assets and liabilities of the retail stores is the difference between the carrying amounts of the derecognized assets and liabilities, and the fair value of consideration received, net of costs to sell.

Acreage Arrangement and Amendme

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	9 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	29 . ACREAGE ARRANGEMENT AND AMENDMENTS TO CBI INVESTOR RIGHTS AGREEMENT AND WARRANTS Acreage Arrangement On September 23, 2020, the Company and Acreage entered into a second amendment (the “Acreage Amending Agreement”) to the arrangement agreement (the “Original Acreage Arrangement Agreement”) and plan of arrangement (the “Original Acreage Arrangement”) between the Company and Acreage dated April 18, 2019, as amended on May 15, 2019. In connection with the Acreage Amending Agreement, the Company and Acreage implemented an amended and restated plan of arrangement (the “Acreage Amended Arrangement”) on September 23, 2020. Pursuant to the terms of the Original Acreage Arrangement, shareholders of Acreage and holders of certain securities convertible into the existing Acreage subordinated voting shares as of June 26, 2019, received an immediate aggregate total payment of US$ 300,000 ($ 395,190 ) in exchange for granting Canopy Growth both the right and the obligation to acquire all of the issued and outstanding shares of Acreage following the occurrence or waiver of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and subject to the satisfaction or waiver of the conditions set out in the Original Acreage Arrangement Agreement. The Acreage Amended Arrangement provides for, among other things, the following: • Following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Original Acreage Arrangement Agreement (as modified in connection with the Acreage Amending Agreement), Canopy Growth will acquire all of the issued and outstanding Fixed Shares based on an amended exchange ratio equal to 0.3048 of a common share to be received for each Fixed Share held. The foregoing exchange ratio for the Fixed Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if, among other things, Acreage issues greater than the permitted number of Fixed Shares; • Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right (the "Acreage Floating Option") exercisable for a period of 30 days, to acquire all of the issued and outstanding Floating Shares for cash or common shares or a combination thereof, in Canopy Growth’s sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the Canadian Securities Exchange, subject to a minimum call price of US$ 6.41 per Floating Share. The foregoing exchange ratio for the Floating Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if Acreage issues greater than the permitted number of Floating Shares. The acquisition of the Floating Shares, if acquired, will take place concurrently with the closing of the acquisition of the Fixed Shares; • Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Class F multiple voting share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares; • If the occurrence or waiver of the Triggering Event does not occur by September 23, 2030, Canopy Growth’s rights to acquire both the Fixed Shares and the Floating Shares will terminate; • Upon implementation of the Acreage Amended Arrangement, Canopy Growth made a cash payment to the shareholders of Acreage and holders of certain convertible securities in the aggregate amount of US$ 37,500 ($ 49,849 ); and • Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares. See Note 3 for information regarding the Reorganization. In connection with the Reorganization, Canopy Growth irrevocably waived the Acreage Floating Option and subject to, among other things, the terms of the Floating Share Arrangement Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by the Company, which is expected to enable Canopy USA, following, among other things, the Meeting and the exercise of the Acreage Option, including the issuance of the Fixed Shares to Canopy USA, to consummate the acquisitions of Acreage, Wana and Jetty. At December 31, 2022, the right and the obligation (the “Acreage financial instrument”) to acquire the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement represents a financial asset of $ 37,000 (March 31, 2022 – $ 47,000 liability), as the estimated fair value of the Acreage business is more than the estimated fair value of the consideration to be provided upon the exercise of the Acreage financial instrument. Fair value changes on the Acreage financial instrument are recognized in other income (expense), net; see Note 24. The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 22 for additional details on how the fair value of the Acreage financial instrument is calculated on a recurring basis. From a measurement perspective, the Company has elected the fair value option under ASC 825 - Financial Instruments ("ASC 825"). In connection with the Acreage Amended Arrangement, on September 23, 2020, an affiliate of the Company advanced US$ 50,000 ($ 66,995 ) to Universal Hemp, LLC, a wholly owned subsidiary of Acreage (“Acreage Hempco”) pursuant to a secured debenture (“Hempco Debenture”). In accordance with the terms of the Hempco Debenture, the funds advanced to Acreage Hempco cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. The Hempco Debenture bears interest at a rate of 6.1 % per annum and matures on September 23, 2030, or such earlier date in accordance with the terms of the Hempco Debenture. All interest payments made pursuant to the Hempco Debenture are payable in cash by Acreage Hempco. The Hempco Debenture is not convertible and is not guaranteed by Acreage. In connection with the Reorganization, as described in Note 3, on October 24, 2022, the Company transferred the Hempco Debenture to Canopy USA. The amount advanced on September 23, 2020 pursuant to the Hempco Debenture has been recorded in other financial assets (see Note 10), and the Company has elected the fair value option under ASC 825 (see Note 22). At December 31, 2022, the estimated fair value of the Hempco Debenture issued to an affiliate of the Company by Acreage Hempco was $ 27,853 (March 31, 2022 – $ 28,824 ), measured using a discounted cash flow model (see Note 22). Refer to Note 10 for details on fair value changes, foreign currency translation adjustment, and interest received. An additional US$ 50,000 may be advanced pursuant to the Hempco Debenture subject to the satisfaction of certain conditions by Acreage Hempco. Amendment to the CBI Investor Rights Agreement and warrants On April 18, 2019, certain wholly-owned subsidiaries of CBI and Canopy Growth entered into the Second Amended and Restated Investor Rights Agreement and a consent agreement. In connection with these agreements, on June 27, 2019, Canopy Growth (i) extended the term of the first tranche of warrants, which allow CBI to acquire 88.5 million additional shares of Canopy Growth for a fixed price of $ 50.40 per share (the “Tranche A Warrants”), to November 1, 2023 ; and (ii) replaced the second tranche of warrants with two new tranches of warrants (the “Tranche B Warrants” and the “Tranche C Warrants”) as follows: • the Tranche B Warrants are exercisable to acquire 38.5 million common shares at a price of C$ 76.68 per common share; and • the Tranche C Warrants are exercisable to acquire 12.8 million common shares at a price equal to the 5-day volume-weighted average price of the common shares immediately prior to exercise. In connection with the Tranche B Warrants and the Tranche C Warrants, Canopy Growth will provide CBI with a share repurchase credit of up to $ 1.583 billion on the aggregate exercise price of the Tranche B Warrants and Tranche C Warrants in the event that Canopy Growth does not purchase for cancellation the lesser of (i) 27,378,866 common shares; and (ii) common shares with a value of $ 1.583 billion, during the period commencing on April 18, 2019 and ending on the date that is 24 months after the date that CBI exercises all of the Tranche A Warrants. The share repurchase credit feature is accounted for as a derivative liability, with the fair value continuing to be $ nil at December 31, 2022. The modifications to the Tranche A Warrants resulted in them meeting the definition of a derivative instrument under ASC 815 - Derivatives and Hedging (“ASC 815”). They continue to be classified in equity as the number of shares and exercise price were both fixed at inception. The Tranche B Warrants are accounted for as derivative instruments (the “warrant derivative liability”) measured at fair value in accordance with ASC 815. At December 31, 2022, the fair value of the warrant derivative liability was $ 668 (March 31, 2022 – $ 26,920 ), and fair value changes are recognized in other income (expense), net; see Note 24. See Note 22 for additional details on how the fair value of the warrant derivative liability is calculated on a recurring basis. The Tranche C Warrants are accounted for as derivative instruments, with the fair value continuing to be $nil at December 31, 2022. As described in Note 3 , in connection with the Reorganization, the Company entered into the Consent Agreement, pursuant to which CBG and Greenstar agreed, among other things, that in the event that CBG and Greenstar convert their ownership in the Company's common shares into Exchangeable Shares, CBG will surrender the warrants held by CBG to purchase 139,745,453 common shares of the Company for cancellation for no consideration.

Segment Information

Segment Information	9 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information	30 . SEGMENT INFORMATION Reportable segments Prior to the three months ended September 30, 2022, the Company had the following two reportable segments: (i) global cannabis; and (ii) other consumer products. Following the completion of certain restructuring actions which were initiated in the three months ended March 31, 2022, and which were aligned with the Company's strategic review of its business, the Company has changed the structure of its internal management financial reporting. Accordingly, in the three months ended September 30, 2022, the Company began reporting its financial results for the following five reportable segments: • Canada cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis products in Canada pursuant to the Cannabis Act ; • Rest-of-world cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis products internationally pursuant to applicable international legislation, regulations and permits; • Storz & Bickel - includes the production, distribution and sale of vaporizers; • BioSteel - includes the production, distribution and sale of consumer packaged goods ("CPG") including sports nutrition beverages, mixes, protein, gum and mints, some of which have been blended with hemp-derived CBD isolate; and • This Works - includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. Accordingly, information regarding segment net revenue and segment gross margin for the comparative periods has been restated to reflect the aforementioned change in reportable segments. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other". Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Segmented net revenue Canada cannabis $ 46,617 $ 60,678 $ 151,336 $ 205,879 Rest-of-world cannabis 5,846 22,299 30,179 65,362 Storz & Bickel 20,214 25,205 49,351 63,786 BioSteel 16,363 16,974 64,173 31,147 This Works 8,289 10,730 20,677 26,308 Other 3,884 5,086 13,475 16,073 $ 101,213 $ 140,972 $ 329,191 $ 408,555 Segmented gross margin: Canada cannabis $ ( 5,281 ) $ ( 13,121 ) ( 25,466 ) $ ( 97,925 ) Rest-of-world cannabis ( 2,184 ) 4,660 ( 3,676 ) 24,245 Storz & Bickel 9,186 11,172 20,809 27,623 BioSteel ( 7,669 ) 1,352 ( 804 ) ( 2,361 ) This Works 4,032 5,469 8,982 12,423 Other ( 525 ) 558 143 2,183 ( 2,441 ) 10,090 ( 12 ) ( 33,812 ) Selling, general and administrative expenses 122,636 116,835 351,891 355,165 Share-based compensation 6,428 6,777 21,725 35,856 Asset impairment and restructuring costs 22,259 36,439 1,794,212 128,198 Operating loss ( 153,764 ) ( 149,961 ) ( 2,167,840 ) ( 553,031 ) Loss from equity method investments - - - ( 100 ) Other income (expense), net ( 113,340 ) 34,282 ( 406,762 ) 810,769 (Loss) income before incomes taxes $ ( 267,104 ) $ ( 115,679 ) $ ( 2,574,602 ) $ 257,638 Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance. Entity-wide disclosures Disaggregation of net revenue by geographic area: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Canada $ 65,851 $ 78,644 $ 226,312 $ 241,440 Germany 12,772 23,143 36,383 71,619 United States 10,292 22,764 30,688 60,856 Other 12,298 16,421 35,808 34,640 $ 101,213 $ 140,972 $ 329,191 $ 408,555 Disaggregation of property, plant and equipment by geographic area: December 31, March 31, 2022 2022 Canada $ 726,613 $ 827,591 United States 96,159 63,247 Other 51,257 51,942 $ 874,029 $ 942,780 For the three months ended December 31, 2022, no customer represented more than 10% of the Company’s net revenue (three months ended December 31, 2021 – none ). For the nine months ended December 31, 2022, no customer represented more than 10% of the Company's net revenue (nine months ended December 31, 2021 – one )

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	. SUBSEQUENT EVENTS Canadian Cannabis Operations Restructuring On February 9, 2023, the Company announced a series of comprehensive steps to align its Canadian cannabis operations and resources in response to unfavorable market realities, which include: • Transitioning to an asset-light model by: (i) exiting cannabis flower cultivation in the Company's Smiths Falls, Ontario facility; (ii) ceasing the sourcing of cannabis flower from the Company's Mirabel, Quebec facility; and (iii) consolidating cultivation at the Company's existing facilities in Kincardine, Ontario and Kelowna, British Columbia; • Moving to an adaptive third-party sourcing model for all cannabis beverages, edibles, vapes, and extracts which will enable the Company to select and bring to market new product formats without the required investment in research and development and production footprint; • As a result of the aforementioned changes, the Company intends to consolidate flower, pre-rolled joints, softgel, and oil manufacturing in the Company’s current beverage production facility in Smiths Falls, Ontario and reduce headcount across the business; and • The Company intends to close the 1 Hershey Drive facility in Smiths Falls, Ontario and the Company is in active discussions with respect to restructuring the joint-venture entity which holds the cultivation facility in Mirabel, Quebec.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The accompanying condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 21 .
Use of estimates	Use of estimates The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06 , Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by removing the separation models for convertible debt instruments and convertible preferred stock with (1) cash conversion features, and (2) beneficial conversion features. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company adopted the guidance on April 1, 2022, using the modified retrospective approach with the cumulative effect recognized as an adjustment to the opening deficit balance, and, accordingly, prior period balances and disclosures have not been restated. Upon adoption of ASU 2020-06, the Supreme Debentures (as defined below) will be accounted for under the separation model for a substantial premium instead of a beneficial conversion feature resulting in an increased debt discount to be amortized over the life of the instrument. The adoption of this guidance resulted in increased additional paid-in capital by $ 4,452 , decreased long-term debt by $ 3,723 , and decreased accumulated deficit by $ 729 for non-cash accretion expense prior to April 1, 2022.

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Dec. 31, 2022
Cash And Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	The components of cash and cash equivalents are as follows: December 31, March 31, 2022 2022 Cash $ 524,979 $ 470,682 Cash equivalents 73,152 305,323 $ 598,131 $ 776,005

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Dec. 31, 2022
Short Term Investments [Abstract]
Components of Short-term Investments	The components of short-term investments are as follows: December 31, March 31, 2022 2022 Term deposits $ 98,286 $ 319,092 Asset-backed securities 80,924 21,905 Government securities - 22,253 Commercial paper and other 11,909 232,401 $ 191,119 $ 595,651

Amounts Receivable, Net (Tables

Amounts Receivable, Net (Tables)	9 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Components of Amounts Receivable, Net	The components of amounts receivable, net are as follows: December 31, March 31, 2022 2022 Accounts receivable, net $ 85,297 $ 78,059 Indirect taxes receivable 7,835 7,524 Interest receivable 2,585 4,406 Other receivables 8,923 6,454 $ 104,640 $ 96,443

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory are as follows: December 31, March 31, 2022 2022 Raw materials, packaging supplies and consumables $ 34,940 $ 26,821 Work in progress 64,483 65,245 Finished goods 114,514 112,321 $ 213,937 $ 204,387

Prepaid Expenses and Other As_2

Prepaid Expenses and Other Assets (Tables)	9 Months Ended
	Dec. 31, 2022
Prepaid Expense And Other Assets Current [Abstract]
Components of Prepaid and Other Assets	The components of prepaid expenses and other assets are as follows: December 31, March 31, 2022 2022 Prepaid expenses $ 28,736 $ 23,041 Deposits 7,740 10,145 Prepaid inventory 786 449 Other assets 14,889 19,065 $ 52,151 $ 52,700

Other Financial Assets (Tables)

Other Financial Assets (Tables)	9 Months Ended
	Dec. 31, 2022
Schedule Of Investments [Abstract]
Summary of Changes in Other Financial Assets	The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 22. Foreign Balance at currency Balance at March 31, Fair value translation December 31, Entity Instrument 2022 Additions changes adjustments Other 2022 Acreage 1 Option $ - $ - $ 37,000 $ - $ - $ 37,000 TerrAscend Exchangeable Shares Exchangeable shares 229,000 51,000 ( 207,000 ) - - 73,000 TerrAscend Canada - October 2019 Term loan / debenture 10,280 - ( 146 ) - ( 10,134 ) - TerrAscend Canada - March 2020 Term loan / debenture 49,890 - ( 4,804 ) - ( 45,086 ) - Arise Bioscience Term loan / debenture 13,343 - ( 1,767 ) 1,268 ( 12,844 ) - TerrAscend - October 2019 Warrants 3,730 - ( 3,372 ) - ( 358 ) - TerrAscend - March 2020 Warrants 60,740 - ( 46,376 ) - ( 14,364 ) - TerrAscend - December 2020 Warrants 3,460 - ( 2,246 ) - ( 1,214 ) - TerrAscend - December 2022 Warrants - 33,000 ( 17,500 ) - - 15,500 TerrAscend Option 6,300 - ( 5,050 ) - - 1,250 Wana Option 372,343 - ( 135,405 ) 22,398 - 259,336 Jetty Options - 90,120 ( 9,778 ) 5,048 - 85,390 Acreage Hempco 1 Debenture 28,824 - 874 2,373 ( 4,218 ) 27,853 Acreage Debt Option Premium Option - 38,048 - 581 - 38,629 Acreage Tax Receivable Agreement Other - 41,491 - ( 231 ) - 41,260 Other - at fair value through net income (loss) Various 10,396 - ( 1,185 ) 524 - 9,735 Other - classified as held for investment Loan receivable 12,022 - - - ( 2,588 ) 9,434 $ 800,328 $ 253,659 $ ( 396,755 ) $ 31,961 $ ( 90,806 ) $ 598,387 1 See Note 29 for information regarding the Acreage Arrangement and Acreage Hempco.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2022
Property Plant And Equipment [Abstract]
Summary of Expected Useful Life of Property, Plant and Equipment	The components of property, plant and equipment are as follows: December 31, March 31, 2022 2022 Buildings and greenhouses $ 752,177 $ 766,931 Production and warehouse equipment 140,975 159,314 Leasehold improvements 24,323 69,304 Office and lab equipment 24,263 29,879 Computer equipment 18,060 22,293 Land 17,395 18,917 Right-of-use-assets Buildings and greenhouses 74,153 89,228 Production and warehouse equipment 27 55 Assets in process 12,712 19,771 1,064,085 1,175,692 Less: Accumulated depreciation ( 190,056 ) ( 232,912 ) $ 874,029 $ 942,780

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2022
Intangible Assets Net Excluding Goodwill [Abstract]
Summary of Components of Intangible Assets	The components of intangible assets are as follows: December 31, 2022 March 31, 2022 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 141,488 $ 89,758 $ 138,170 $ 97,638 Distribution channel 72,799 22,045 72,642 24,834 Operating licenses 24,400 19,762 24,400 22,052 Software and domain names 36,464 15,221 29,822 14,206 Brands 5,620 3,128 5,547 3,680 Amortizable intangibles in process 842 842 5,476 5,476 Total $ 281,613 $ 150,756 $ 276,057 $ 167,886 Indefinite lived intangible assets Acquired brands $ 62,774 $ 74,809 Operating licenses - 10,000 Total intangible assets $ 213,530 $ 252,695

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 105,323 Disposal of consolidated entities ( 58,786 ) Impairment losses ( 40,748 ) Foreign currency translation adjustments ( 28,640 ) Balance, March 31, 2022 $ 1,866,503 Disposal of consolidated entities ( 227 ) Impairment losses ( 1,727,679 ) Foreign currency translation adjustments 3,479 Balance, December 31, 2022 $ 142,076

Other Accrued Expenses and Li_2

Other Accrued Expenses and Liabilities (Tables)	9 Months Ended
	Dec. 31, 2022
Accounts Payable And Accrued Liabilities Current [Abstract]
Components of Other Accrued Expenses and Liabilities	The components of other accrued expenses and liabilities are as follows: December 31, March 31, 2022 2022 Employee compensation $ 29,213 $ 24,873 Inventory 951 10,096 Professional fees 6,891 7,640 Taxes and government fees 8,541 7,144 Other 30,389 25,525 $ 75,985 $ 75,278

Debt (Tables)

Debt (Tables)	9 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Summary of Components of Debt	The components of debt are as follows: December 31, March 31, Maturity Date 2022 2022 Unsecured senior notes at 4.25 % interest with July 15, 2023 Principal amount $ 337,380 $ 600,000 Accrued interest 6,731 5,958 Non-credit risk fair value adjustment 19,062 7,140 Credit risk fair value adjustment ( 37,618 ) ( 49,140 ) 325,555 563,958 Convertible debentures September 10, 2025 30,867 32,858 Accretion debentures September 10, 2025 8,506 7,720 Credit facility March 18, 2026 838,407 893,647 Other revolving debt facility, loan, and financings 2,266 2,808 1,205,601 1,500,991 Less: current portion ( 455,483 ) ( 9,296 ) Long-term portion $ 750,118 $ 1,491,695

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Components of Other Liabilities	The components of other liabilities are as follows: As at December 31, 2022 As at March 31, 2022 Current Long-term Total Current Long-term Total Lease liabilities $ 35,537 $ 83,167 $ 118,704 $ 38,035 $ 101,125 $ 139,160 Acquisition consideration 7,908 47,169 55,077 4,020 77,834 81,854 Refund liability 2,937 - 2,937 3,437 - 3,437 Settlement liabilities and 37,752 11,555 49,307 18,562 11,090 29,652 $ 84,134 $ 141,891 $ 226,025 $ 64,054 $ 190,049 $ 254,103

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interest (Tables)	9 Months Ended
	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Summary of Net Changes in Redeemable Noncontrolling Interests	The net changes in the redeemable noncontrolling interests are as follows: Vert BioSteel Total As at March 31, 2022 $ 1,000 $ 35,200 $ 36,200 Net income (loss) attributable to redeemable noncontrolling interest 508 ( 18,316 ) ( 17,808 ) Adjustments to redemption amount ( 508 ) 20,874 20,366 Redemption of redeemable noncontrolling interest - ( 27,350 ) ( 27,350 ) As at December 31, 2022 $ 1,000 $ 10,408 $ 11,408 Vert BioSteel Total As at March 31, 2021 $ 11,500 $ 123,800 $ 135,300 Net income (loss) attributable to redeemable noncontrolling interest ( 2,401 ) ( 10,699 ) ( 13,100 ) Adjustments to redemption amount 2,401 ( 50,792 ) ( 48,391 ) Redemption of redeemable noncontrolling interest ( 5,109 ) ( 5,109 ) As at December 31, 2021 $ 11,500 $ 57,200 $ 68,700

Share Capital (Tables)

Share Capital (Tables)	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Summary of Issuances of Stock Other	During the nine months ended December 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Jetty Agreements 8,426,539 $ 59,013 $ - HSCP Holders pursuant to Amended TRA 5,648,927 20,630 - Completion of acquisition milestones 222,421 1,379 ( 1,379 ) Other issuances 237,802 1,209 ( 353 ) Total 14,535,689 $ 82,231 $ ( 1,732 ) For the three and nine months ended December 31, 2022 , the Company also issued 8,692,128 common shares with a value of $ 26,506 relating to its redemption of the redeemable noncontrolling interest in BioSteel. The redemption increases the Company's interest in BioSteel from 78.6 % to 90.3 %. During the nine months ended December 31, 2021 , the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 ( 29,721 ) Other issuances 351,252 6,630 ( 405 ) Total 10,659,937 $ 296,574 $ ( 30,126 )
Summary of Warrants	Number of Average Warrant Balance outstanding at March 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 Expiry of warrants - - - Balance outstanding at December 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 1 This balance excludes the Tranche C Warrants (as defined below), which represent a derivative liability and have nominal value. See Note 29. Number of Average Warrant Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants ( 145,831 ) 32.61 - Balance outstanding at December 31, 2021 1 128,193,047 $ 58.04 $ 2,581,788 1 This balance excludes the Tranche C Warrants, which represent a derivative liability and have nominal value. See Note 29 .

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Changes in Options Outstanding	The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2022: Options Weighted Balance outstanding at March 31, 2022 16,782,962 $ 33.89 Options granted 4,651,176 4.94 Options exercised ( 76,929 ) 3.41 Options forfeited ( 6,058,172 ) 29.37 Balance outstanding at December 31, 2022 15,299,037 $ 27.07
Summary of Options Outstanding	The following is a summary of the Options outstanding as at December 31, 2022: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices December 31, 2022 (years) December 31, 2022 (years) $ 0.06 - $ 24.62 6,083,908 4.83 1,369,076 2.77 $ 24.63 - $ 33.53 3,281,232 2.58 2,033,996 2.24 $ 33.54 - $ 36.80 1,569,568 1.94 1,569,568 1.94 $ 36.81 - $ 42.84 1,800,926 2.05 1,794,649 2.02 $ 42.85 - $ 67.64 2,563,403 2.10 2,563,403 2.10 15,299,037 3.27 9,330,692 2.19
Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model	The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2022 and 2021, on their measurement date by applying the following assumptions: December 31, December 31, 2022 2021 Risk-free interest rate 3.47 % 1.21 % Expected life of options (years) 3 - 5 3 - 5 Expected volatility 82 % 75 % Expected forfeiture rate 20 % 18 % Expected dividend yield nil nil Black-Scholes value of each option $ 3.34 $ 7.55
Summary of Changes in RSUs and PSUs	The following is a summary of the changes in the Company’s RSUs and PSUs during the nine months ended December 31, 2022: Number of RSUs Balance outstanding at March 31, 2022 3,477,292 RSUs and PSUs granted 3,128,198 RSUs and PSUs released ( 359,628 ) RSUs and PSUs cancelled and forfeited ( 1,925,026 ) Balance outstanding at December 31, 2022 4,320,836

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2022 $ ( 57,468 ) $ 15,186 $ ( 42,282 ) Settlement of unsecured senior notes, net of tax - ( 29,507 ) ( 29,507 ) Other comprehensive income 24,694 32,847 57,541 As at December 31, 2022 $ ( 32,774 ) $ 18,526 $ ( 14,248 ) Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2021 $ ( 28,246 ) $ ( 5,994 ) $ ( 34,240 ) Other comprehensive (loss) income ( 18,767 ) 26,280 7,513 As at December 31, 2021 $ ( 47,013 ) $ 20,286 $ ( 26,727 )

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	9 Months Ended
	Dec. 31, 2022
Noncontrolling Interest [Abstract]
Summary of Net Change in Noncontrolling Interests	The net change in the noncontrolling interests is as follows: Vert BioSteel Other Total As at March 31, 2022 $ - $ 2,497 $ 1,844 $ 4,341 Comprehensive income (loss) 508 ( 18,316 ) ( 1,844 ) ( 19,652 ) Net (income) loss attributable to redeemable noncontrolling ( 508 ) 18,316 - 17,808 Share-based compensation - 495 - 495 Ownership changes - ( 1,552 ) 1,356 ( 196 ) As at December 31, 2022 $ - $ 1,440 $ 1,356 $ 2,796 Vert BioSteel Other non- Total As at March 31, 2021 $ - $ 1,658 $ 3,051 $ 4,709 Comprehensive loss ( 2,401 ) ( 10,699 ) ( 1,207 ) ( 14,307 ) Net loss attributable to redeemable noncontrolling interest 2,401 10,699 - 13,100 Share-based compensation - 684 - 684 As at December 31, 2021 $ - $ 2,342 $ 1,844 $ 4,186

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Dec. 31, 2022
Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis	The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2022 Assets: Short-term investments $ 191,119 $ - $ - $ 191,119 Restricted short-term investments 12,932 - - 12,932 Other financial assets 251 - 508,813 509,064 Liabilities: Unsecured senior notes - 325,555 - 325,555 Warrant derivative liability - - 668 668 Other liabilities - - 43,102 43,102 March 31, 2022 Assets: Short-term investments $ 595,651 $ - $ - $ 595,651 Restricted short-term investments 12,216 - - 12,216 Other financial assets 490 - 787,816 788,306 Liabilities: Unsecured senior notes - 563,958 - 563,958 Liability arising from Acreage Arrangement - - 47,000 47,000 Warrant derivative liability - - 26,920 26,920 Other liabilities - - 70,066 70,066
Level 2
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Unsecured senior notes Senior note pricing model Quoted prices in over-the-counter broker market
Level 3
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - December 2022 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Wana financial instrument - Call Discounted cash flow Expected future Wana cash flows Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value Option Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana equity Increase or decrease in volatility will result in an increase or decrease in fair value Jetty financial instrument - Discounted cash flow Expected future Jetty cash flows Increase or decrease in expected future Jetty cash flows will result in an increase or decrease in fair value Call Option Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Jetty financial instrument - Deferred Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Payments Volatility of Jetty equity and revenue Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Expected future BioSteel cash flows Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value Vert Mirabel redeemable Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value noncontrolling interest Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Dec. 31, 2022
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenue	Revenue is disaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Canada cannabis Canadian adult-use cannabis Business-to-business 1 $ 21,522 $ 33,282 $ 73,379 $ 117,902 Business-to-consumer 11,036 14,477 36,243 48,473 32,558 47,759 109,622 166,375 Canadian medical cannabis 2 14,059 12,919 41,714 39,504 $ 46,617 $ 60,678 $ 151,336 $ 205,879 Rest-of-world cannabis C 3 - 9,675 - 33,005 Other rest-of-world cannabis 5,846 12,624 30,179 32,357 $ 5,846 $ 22,299 $ 30,179 $ 65,362 Storz & Bickel $ 20,214 $ 25,205 $ 49,351 $ 63,786 BioSteel $ 16,363 $ 16,974 $ 64,173 $ 31,147 This Works $ 8,289 $ 10,730 $ 20,677 $ 26,308 Other 3,884 5,086 13,475 16,073 Net revenue $ 101,213 $ 140,972 $ 329,191 $ 408,555 1 Canadian adult-use business-to-business net revenue during the three and nine months ended December 31, 2022 reflects excise taxes of $ 10,797 and $ 33,754 , respectively (three and nine months ended December 31, 2021 – $ 12,754 and $ 43,501 , respectively). 2 Canadian medical cannabis net revenue for the three and nine months ended December 31, 2022 reflects excise taxes of $ 1,339 and $ 3,625 , respectively (three and nine months ended December 31, 2021 – $ 1,298 and $ 4,039 , respectively).

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	9 Months Ended
	Dec. 31, 2022
Other Income And Expenses [Abstract]
Schedule of Other Income (Expense), Net	Other income (expense), net is disaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Fair value changes on other financial assets $ ( 95,815 ) $ ( 68,666 ) $ ( 396,755 ) $ ( 263,946 ) Fair value changes on liability arising from Acreage - 59,000 47,000 497,000 Fair value changes on unsecured senior notes ( 8,964 ) 606 ( 32,365 ) 81,342 Fair value changes on warrant derivative liability 23 67,282 26,252 578,084 Fair value changes on acquisition related contingent 1,762 712 25,902 544 Gain (loss) and charges related to settlement of debt 8,912 - 4,224 - Interest income 7,048 1,575 15,922 6,977 Interest expense ( 33,288 ) ( 26,408 ) ( 90,660 ) ( 77,618 ) Foreign currency gain (loss) 2,966 990 ( 8,828 ) 2,902 Gain (loss) on disposal/acquisition of consolidated entity 4,142 - 6,223 ( 1,653 ) Other income (expense), net ( 126 ) ( 809 ) ( 3,677 ) ( 12,863 ) $ ( 113,340 ) $ 34,282 $ ( 406,762 ) $ 810,769

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Basic and diluted earnings (loss) per share are calculated using the following numerators and denominators: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Basic (loss) earnings per share computation Net (loss) income attributable to common shareholders of $ ( 261,583 ) $ ( 108,925 ) $ ( 2,566,537 ) $ 272,435 Weighted average number of common shares outstanding 486,112,598 393,818,282 453,237,882 390,423,083 Basic (loss) earnings per share $ ( 0.54 ) $ ( 0.28 ) $ ( 5.66 ) $ 0.70 Diluted (loss) earnings per share computation Net (loss) income used in the computation of basic (loss) $ ( 261,583 ) $ ( 108,925 ) $ ( 2,566,537 ) $ 272,435 Numerator adjustments for diluted (loss) earnings per share: Adjustment to net loss attributable to noncontrolling - - - ( 13,100 ) Removal of fair value changes on unsecured senior notes - - - ( 81,342 ) Net (loss) income used in the computation of diluted (loss) $ ( 261,583 ) $ ( 108,925 ) $ ( 2,566,537 ) $ 177,993 Weighted average number of common shares outstanding 486,112,598 393,818,282 453,237,882 390,423,083 Denominator adjustments for diluted (loss) earnings per Dilutive impact of assumed exercise or conversion of: Unsecured senior notes - - - 12,454,620 Redeemable noncontrolling interest - - - 4,528,898 Stock options - - - 745,700 Other securities - - - 2,834,501 Weighted average number of common shares for 486,112,598 393,818,282 453,237,882 410,986,802 Diluted (loss) earnings per share 1 $ ( 0.54 ) $ ( 0.28 ) $ ( 5.66 ) $ 0.43 1 In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive.

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combination	The following table summarizes the consolidated balance sheet impact at acquisition of the Company's business combination that occurred in the nine months ended December 31, 2022: Verona Manufacturing Facility Property, plant and equipment $ 28,771 Debt and other liabilities ( 2,373 ) Net assets acquired $ 26,398 Consideration paid in cash $ 24,223 Other consideration 2,175 Total consideration $ 26,398 Consideration paid in cash $ 24,223 Less: Cash and cash equivalents acquired - Net cash outflow $ 24,223

Retail Divestiture (Tables)

Retail Divestiture (Tables)	9 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Summary of Derecognized Assets and Liabilities Transferred	Following the divestiture of the retail stores pursuant to the OEGRC Transaction and the FOUR20 Transaction, the Company derecognized the assets and liabilities of the associated retail stores from these consolidated financial statements at their carrying amounts on their respective closing dates, as follows: Current assets $ 6,461 Property, plant and equipment 7,990 Other long-term assets 144 Current liabilities ( 9,492 ) Net assets disposed $ 5,103 Consideration received in cash $ 88 Future cash consideration 11,599 Costs to sell ( 2,442 ) Total consideration $ 9,245 Gain on disposal of consolidated entity $ 4,142

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated	Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Segmented net revenue Canada cannabis $ 46,617 $ 60,678 $ 151,336 $ 205,879 Rest-of-world cannabis 5,846 22,299 30,179 65,362 Storz & Bickel 20,214 25,205 49,351 63,786 BioSteel 16,363 16,974 64,173 31,147 This Works 8,289 10,730 20,677 26,308 Other 3,884 5,086 13,475 16,073 $ 101,213 $ 140,972 $ 329,191 $ 408,555 Segmented gross margin: Canada cannabis $ ( 5,281 ) $ ( 13,121 ) ( 25,466 ) $ ( 97,925 ) Rest-of-world cannabis ( 2,184 ) 4,660 ( 3,676 ) 24,245 Storz & Bickel 9,186 11,172 20,809 27,623 BioSteel ( 7,669 ) 1,352 ( 804 ) ( 2,361 ) This Works 4,032 5,469 8,982 12,423 Other ( 525 ) 558 143 2,183 ( 2,441 ) 10,090 ( 12 ) ( 33,812 ) Selling, general and administrative expenses 122,636 116,835 351,891 355,165 Share-based compensation 6,428 6,777 21,725 35,856 Asset impairment and restructuring costs 22,259 36,439 1,794,212 128,198 Operating loss ( 153,764 ) ( 149,961 ) ( 2,167,840 ) ( 553,031 ) Loss from equity method investments - - - ( 100 ) Other income (expense), net ( 113,340 ) 34,282 ( 406,762 ) 810,769 (Loss) income before incomes taxes $ ( 267,104 ) $ ( 115,679 ) $ ( 2,574,602 ) $ 257,638
Summary of Disaggregation of Net Revenue by Geographic Area	Disaggregation of net revenue by geographic area: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2022 2021 2022 2021 Canada $ 65,851 $ 78,644 $ 226,312 $ 241,440 Germany 12,772 23,143 36,383 71,619 United States 10,292 22,764 30,688 60,856 Other 12,298 16,421 35,808 34,640 $ 101,213 $ 140,972 $ 329,191 $ 408,555
Summary of Disaggregation of Property, Plant and Equipment by Geographic Area	Disaggregation of property, plant and equipment by geographic area: December 31, March 31, 2022 2022 Canada $ 726,613 $ 827,591 United States 96,159 63,247 Other 51,257 51,942 $ 874,029 $ 942,780

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2022
Basis Of Presentation [Line Items]
Long-term debt	$ 563,958	$ 325,555
Accumulated deficit	$ (6,370,337)	$ (8,937,603)
Accounting Standards Update [Extensible Enumeration]	us-gaap:AccountingStandardsUpdate202006Member
Cumulative effect from adoption of ASU 2020-06
Basis Of Presentation [Line Items]
Additional paid in capital	$ 4,452
Long-term debt	3,723
Accumulated deficit	$ 729

Canopy USA - Additional Informa

Canopy USA - Additional Information (Details)

9 Months Ended

Dec. 09, 2022 shares

Nov. 10, 2022 CAD ($)

Nov. 10, 2022 USD ($)

Oct. 24, 2022 USD ($) $ / shares shares

Mar. 18, 2021 USD ($) $ / shares

Sep. 23, 2020

Dec. 31, 2022 CAD ($) shares

Dec. 31, 2021 CAD ($)

Nov. 10, 2022 USD ($)

Oct. 24, 2022 CAD ($) $ / shares shares

Oct. 24, 2022 USD ($) $ / shares shares

Jun. 29, 2022 CAD ($)

May 17, 2022

Mar. 31, 2022 CAD ($) shares

Apr. 18, 2019

Jun. 20, 2018 CAD ($)

Reorganization [Line Items]

Warrant expiration date

Dec. 31, 2032

Nov. 01, 2023

Percentage ownership of wholly owned subsidiaries

100%

Minimum percentage of votes cast for approval of amendment proposal

66%

Debt instrument discounted price

$ 930,000

$ 930,000

Paydown

$ 117,951,000

$ 50,217,000

Minimum liquidity, each fiscal quarter

200,000,000

Common stock, shares issued | shares

494,891,390

394,422,604

Common stock value

$ 7,867,310,000

$ 7,482,809,000

Aggregate stock repurchase amount

$ 2,000,000

Description of potential changes in structure

Company is prepared to make changes to the structure of its interest in Canopy USA such that Canopy Growth would not be required to consolidate the financial results of Canopy USA into Canopy Growth’s financial statements, which may include: (1) reducing Canopy Growth’s economic interest in Canopy USA on an as-converted basis to no greater than 90%; (2) reducing the number of managers on Canopy USA’s board of managers from four to three, including, reducing Canopy Growth’s nomination right to a single manager; (3) modifying the terms of the Protection Agreement and Canopy USA’s Limited Liability Company Agreement in order to eliminate certain negative covenants; and (4) modifying the terms of the agreements with third-party investors in Canopy USA to, among other things, eliminate their right to guaranteed returns

Credit Facility

Reorganization [Line Items]

Principal amount

$ 750,000

Debt instrument discounted price per us dollar | $ / shares

$ 1,000

$ 1,000

Paydown

$ 174,375,000

$ 174,375,000

Paydown Agreement [Member]

Reorganization [Line Items]

Principal amount

100,000,000

Minimum liquidity, each fiscal quarter

100,000,000

Additional incremental term loan facility

500,000,000

Paydown Agreement [Member] | Credit Facility

Reorganization [Line Items]

Principal amount

$ 187,500

$ 187,500,000

Paydown

$ 117,528,000

$ 87,852,000

Aggregate principal payment amount

$ 126,324,000

$ 94,427,000

Credit Agreement Amendments

Reorganization [Line Items]

Principal amount

100,000,000

Minimum liquidity, each fiscal quarter

100,000,000

Additional incremental term loan facility

$ 500,000,000

4.25% Senior Notes [Member]

Reorganization [Line Items]

Principal amount

$ 337,380,000

$ 262,620,000

$ 600,000,000

$ 600,000,000

Annual interest rate

4.25%

4.25%

4.25%

4.25%

Warrants

Reorganization [Line Items]

Common stock, shares issued | shares

139,745,453

139,745,453

139,745,453

Common stock value

$ 0

TerrAscend Option | Equity Option

Reorganization [Line Items]

Business acquisition additional number of shares issuable | shares

1,072,450

1,072,450

Aggregate purchase price of stock options | $ / shares

$ 1

TerrAscend Exchangeable Shares

Reorganization [Line Items]

Exchangeable shares in the capital | shares

24,601,467

38,890,570

38,890,570

TerrAscend Warrants

Reorganization [Line Items]

Common share purchase warrants in the capital | shares

22,474,130

22,474,130

Wana Repurchase Right

Reorganization [Line Items]

Accrued annual interest rate percentage.

10%

VCo Ventures

Reorganization [Line Items]

Percentage non-voting shares in capital

99.30%

Common stock, shares issued | shares

1,000,000

1,000,000

Common stock value

$ 1,000,000

Wana

Reorganization [Line Items]

Ownership percentage

100%

100%

Aggregate exercise price of common shares | $ / shares

$ 3

Percentage of common share to be issued

7.50%

Jetty

Reorganization [Line Items]

Ownership percentage

100%

100%

100%

Acreage

Reorganization [Line Items]

Common stock value

$ 19,559,000

Maximum | VCo Ventures

Reorganization [Line Items]

Date of stock repurchase

Mar. 31, 2023

Maximum | Jetty

Reorganization [Line Items]

Ownership percentage

100%

Fixed Shares | Acreage

Reorganization [Line Items]

Common stock shares conversion ratio

0.3048

Fixed Shares | Acreage | Class E Subordinated Voting Shares

Reorganization [Line Items]

Percentage of outstanding shares purchased

70%

70%

Common stock shares conversion ratio

0.3048

0.3048

Floating Shares

Reorganization [Line Items]

Number of canopy shares exchanged | shares

0.45

Floating Shares | Acreage

Reorganization [Line Items]

Percentage of variable interest entity ownership

7.30%

Floating Shares | Acreage | Class D Subordinated Voting Shares

Reorganization [Line Items]

Number of canopy shares exchanged | shares

0.45

Asset Impairment and Restruct_2

Asset Impairment and Restructuring Costs - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss		$ 2,311			$ 1,727,679		$ 40,748
Asset impairment and restructuring costs	$ 22,259			$ 36,439	$ 1,794,212	$ 128,198
Canada Cannabis
Restructuring Cost And Reserve [Line Items]
Asset impairment charges	$ 10,600
Cannabis Operations Reporting Unit
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss			$ 1,725,368

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Cash And Cash Equivalents [Abstract]
Cash	$ 524,979	$ 470,682
Cash equivalents	73,152	305,323
Cash and cash equivalents	$ 598,131	$ 776,005

Short-term Investments - Compon

Short-term Investments - Components of Short-term Investments (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Marketable Securities [Line Items]
Short-term investments	$ 191,119	$ 595,651
Term Deposits
Marketable Securities [Line Items]
Short-term investments	98,286	319,092
Asset-backed Securities
Marketable Securities [Line Items]
Short-term investments	80,924	21,905
Government securities
Marketable Securities [Line Items]
Short-term investments		22,253
Commercial Paper and Other
Marketable Securities [Line Items]
Short-term investments	$ 11,909	$ 232,401

Short-term Investments - Additi

Short-term Investments - Additional Information (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Short Term Investments [Abstract]
Amortized cost of short-term investments	$ 193,537	$ 599,862

Amounts Receivable, Net - Compo

Amounts Receivable, Net - Components of Amounts Receivable, Net (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Receivables [Abstract]
Accounts receivable, net	$ 85,297	$ 78,059
Indirect taxes receivable	7,835	7,524
Interest receivable	2,585	4,406
Other receivables	8,923	6,454
Amounts receivable, net	$ 104,640	$ 96,443

Amounts Receivable, Net - Addit

Amounts Receivable, Net - Additional Information (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Receivables [Abstract]
Allowance for doubtful accounts	$ 6,477	$ 4,764

Inventory - Components of Inven

Inventory - Components of Inventory (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Inventory Disclosure [Abstract]
Raw materials, packaging supplies and consumables	$ 34,940	$ 26,821
Work in progress	64,483	65,245
Finished goods	114,514	112,321
Inventory	$ 213,937	$ 204,387

Inventory - Additional Informat

Inventory - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory write-downs	$ 9,820	$ 11,811	$ 32,978	$ 104,662

Prepaid Expenses and Other As_3

Prepaid Expenses and Other Assets - Components of Prepaid and Other Assets (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 28,736	$ 23,041
Deposits	7,740	10,145
Prepaid inventory	786	449
Other assets	14,889	19,065
Prepaid and other assets	$ 52,151	$ 52,700

Other Financial Assets - Summar

Other Financial Assets - Summary of Changes in Other Financial Assets (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2022 CAD ($)
Schedule Of Investments [Line Items]
Beginning balance	$ 800,328
Additions	253,659
Fair value changes	(396,755)
Foreign currency translation adjustments	31,961
Other	(90,806)
Ending balance	598,387
Acreage1 | Equity Option
Schedule Of Investments [Line Items]
Fair value changes	37,000
Ending balance	37,000
TerrAscend Exchangeable Shares | Exchangeable Shares
Schedule Of Investments [Line Items]
Beginning balance	229,000
Additions	51,000
Fair value changes	(207,000)
Ending balance	73,000
TerrAscend Canada - October 2019 | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	10,280
Fair value changes	(146)
Other	(10,134)
TerrAscend Canada March 2020 | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	49,890
Fair value changes	(4,804)
Other	(45,086)
TerrAscend - October 2019 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	3,730
Fair value changes	(3,372)
Other	(358)
TerrAscend - March 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	60,740
Fair value changes	(46,376)
Other	(14,364)
TerrAscend - December 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	3,460
Fair value changes	(2,246)
Other	(1,214)
TerrAscend - December 2022 | Warrants
Schedule Of Investments [Line Items]
Additions	33,000
Fair value changes	(17,500)
Ending balance	15,500
Acreage Hempco1 | Debenture
Schedule Of Investments [Line Items]
Beginning balance	28,824
Fair value changes	874
Foreign currency translation adjustments	2,373
Other	(4,218)
Ending balance	27,853
Acreage Debt Option Premium | Equity Option
Schedule Of Investments [Line Items]
Additions	38,048
Foreign currency translation adjustments	581
Ending balance	38,629
Acreage Tax Receivable Agreement | Other
Schedule Of Investments [Line Items]
Additions	41,491
Foreign currency translation adjustments	(231)
Ending balance	41,260
Arise Bioscience | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	13,343
Fair value changes	(1,767)
Foreign currency translation adjustments	1,268
Other	(12,844)
TerrAscend | Equity Option
Schedule Of Investments [Line Items]
Beginning balance	6,300
Fair value changes	(5,050)
Ending balance	1,250
Wana | Equity Option
Schedule Of Investments [Line Items]
Beginning balance	372,343
Fair value changes	(135,405)
Foreign currency translation adjustments	22,398
Ending balance	259,336
Jetty | Equity Option
Schedule Of Investments [Line Items]
Additions	90,120
Fair value changes	(9,778)
Foreign currency translation adjustments	5,048
Ending balance	85,390
Other At Fair Value Through Net Income (Loss) | Various
Schedule Of Investments [Line Items]
Beginning balance	10,396
Fair value changes	(1,185)
Foreign currency translation adjustments	524
Ending balance	9,735
Other - Classified as Held for Investment | Loan Receivable
Schedule Of Investments [Line Items]
Beginning balance	12,022
Other	(2,588)
Ending balance	$ 9,434

Other Financial Assets - Additi

Other Financial Assets - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands	Dec. 09, 2022 CAD ($) $ / shares shares	Oct. 24, 2022 CAD ($) shares	Oct. 24, 2022 USD ($) shares	May 17, 2022 CAD ($) Tranche Number shares	May 17, 2022 USD ($) Tranche shares	Dec. 31, 2022 CAD ($)	May 17, 2022 USD ($) Number	Mar. 31, 2022 CAD ($)	Apr. 18, 2019
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 89,094
Warrant expiration date	Dec. 31, 2032								Nov. 01, 2023
Common stock value						$ 7,867,310		$ 7,482,809
Settlement liabilities and other						49,307		$ 29,652
Term Loans or Debentures
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 72,191
Jetty Acquisition
Schedule Of Investments [Line Items]
Number of common shares issued | shares				8,426,539	8,426,539
Acreage
Schedule Of Investments [Line Items]
Common shares issued, fair value			$ 30,441
Common stock value		$ 19,559
Number of floating shares issued in first installment. | shares		5,648,927	5,648,927
Amount of floating shares issued in first installment		$ 20,630	$ 15,220
Amount of floating shares issued for second payment		15,220
Settlement liabilities and other		20,630
Purchase of rights under tax receivable agreement asset		41,491
Acreage | Floating Shares
Schedule Of Investments [Line Items]
Outstanding Principal Of Acreage's Debt		150,000
Option Premium Payment		$ 38,048	$ 28,500
Prior Warrants
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	16,903
TerrAscend Arrangement
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	84,000
Conversion of loans from related company into shares of Common Stock	$ 125,467
Conversion of loans from related company into shares of Common Stock, shares | shares	24,601,467
Notional price per share | $ / shares	$ 5.10
Loss on differences in derecognized financial instruments and fair value of financial assets received	$ 5,094
TerrAscend Arrangement | Warrants
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 33,000
Conversion of loans from related company into shares of Common Stock, shares | shares	22,474,130
Exercise price of warrants | $ / shares	$ 6.07
TerrAscend Entities
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares	24,601,467
New TerrAscend Securities
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares	63,492,037
New TerrAscend Securities | Warrants
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares	22,474,130
TerrAscend Exchangeable Shares
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 51,000
Jetty
Schedule Of Investments [Line Items]
Equity Method Investment Ownership Percentage		100%		100%			100%
Number of option agreements | Number				2			2
Proceeds from Warrant Exercises				$ 29,226
Common shares issued, fair value				59,123
Debt Instrument, Fair Value Disclosure				$ 90,120		$ 85,390
Jetty | First Option Agreement
Schedule Of Investments [Line Items]
Number Of Tranches In Which Option Agreement Is Exercisable | Tranche				2	2
Jetty | Second Option Agreement
Schedule Of Investments [Line Items]
Equity Method Investment Ownership Percentage				22.22%			22.22%
Jetty | First Tranche | First Option Agreement
Schedule Of Investments [Line Items]
Equity Method Investment Ownership Percentage				52.78%			52.78%
Jetty | Second Tranche [Member] | First Option Agreement
Schedule Of Investments [Line Items]
Equity Method Investment Ownership Percentage				25%			25%
Jetty | Upfront Payment
Schedule Of Investments [Line Items]
Consideration				$ 88,349
Jetty | U S D
Schedule Of Investments [Line Items]
Proceeds from Warrant Exercises							$ 22,911
Common shares issued, fair value					$ 45,928
Jetty | Maximum
Schedule Of Investments [Line Items]
Equity Method Investment Ownership Percentage				100%			100%

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,064,085	$ 1,175,692
Less: Accumulated depreciation	(190,056)	(232,912)
Property, plant and equipment, net	874,029	942,780
Buildings and Greenhouses
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	752,177	766,931
Buildings and Greenhouses | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	74,153	89,228
Production and Warehouse Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	140,975	159,314
Production and Warehouse Equipment | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	27	55
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	24,323	69,304
Office and Lab Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	24,263	29,879
Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	18,060	22,293
Land
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	17,395	18,917
Assets in Process
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 12,712	$ 19,771

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment			$ 43,185	$ 56,467
Costs Recorded in Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 12,033	$ 13,813	34,423	38,663
Selling, General and Administrative Expenses
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 1,544	$ 5,546	$ 8,762	$ 17,804

Intangible Assets - Summary of

Intangible Assets - Summary of Components of Intangible Assets (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	$ 281,613	$ 276,057
Net Carrying Amount	150,756	167,886
Total intangible assets	213,530	252,695
Intellectual Property
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	141,488	138,170
Net Carrying Amount	89,758	97,638
Distribution Channel
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	72,799	72,642
Net Carrying Amount	22,045	24,834
Operating Licenses
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	24,400	24,400
Net Carrying Amount	19,762	22,052
Indefinite lived intangible assets		10,000
Software and Domain Names
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	36,464	29,822
Net Carrying Amount	15,221	14,206
Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	5,620	5,547
Net Carrying Amount	3,128	3,680
Amortizable Intangibles in Process
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	842	5,476
Net Carrying Amount	842	5,476
Acquired Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Indefinite lived intangible assets	$ 62,774	$ 74,809

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			$ 20,561	$ 27,462
Costs Recorded in Cost of Goods Sold
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 16	$ 19	45	62
Selling, General and Administrative Expenses
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 7,009	$ 10,639	$ 20,516	$ 27,400

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Details) - CAD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2022
Goodwill [Line Items]
Beginning Balance		$ 1,866,503	$ 1,889,354
Purchase accounting allocations			105,323
Impairment losses	$ (2,311)	(1,727,679)	(40,748)
Foreign currency translation adjustments		3,479	(28,640)
Ending Balance		142,076	1,866,503
Consolidated Entities
Goodwill [Line Items]
Disposal of consolidated entities		$ (227)	$ (58,786)

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
Goodwill [Line Items]
Goodwill impairment loss	$ 2,311		$ 1,727,679	$ 40,748
Goodwill			$ 142,076	$ 1,866,503	$ 1,889,354
Cannabis Operations Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss		$ 1,725,368

Other Accrued Expenses and Li_3

Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Accounts Payable And Accrued Liabilities Current [Abstract]
Employee compensation	$ 29,213	$ 24,873
Inventory	951	10,096
Professional fees	6,891	7,640
Taxes and government fees	8,541	7,144
Other	30,389	25,525
Other accrued expenses and liabilities	$ 75,985	$ 75,278

Debt - Summary of Components of

Debt - Summary of Components of Debt (Details) - CAD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Jun. 20, 2018	Mar. 31, 2022	Dec. 31, 2022	Jun. 29, 2022
Debt Instrument [Line Items]
Other revolving debt facility, loan, and financings		$ 2,808	$ 2,266
Total debt		563,958	325,555
Less: current portion		(9,296)	(455,483)
Long-term portion		1,491,695	$ 750,118
4.25% Senior Notes [Member]
Debt Instrument [Line Items]
Debenture maturity date	Jul. 15, 2023		Jul. 15, 2023
Principal amount	$ 600,000	600,000	$ 337,380	$ 262,620
Accrued interest		5,958	6,731
Non-credit risk fair value adjustment		7,140	19,062
Credit risk fair value adjustment		(49,140)	(37,618)
Senior Notes		1,500,991	$ 1,205,601
Convertible Debentures
Debt Instrument [Line Items]
Convertible debentures			Sep. 10, 2025
Convertible debentures		32,858	$ 30,867
Accretion Debentures
Debt Instrument [Line Items]
Convertible debentures			Sep. 10, 2025
Accretion debentures		7,720	$ 8,506
Revolving Credit Facility
Debt Instrument [Line Items]
Convertible debentures			Mar. 18, 2026
Credit facility		$ 893,647	$ 838,407

Debt - Summary of Components _2

Debt - Summary of Components of Debt (Parenthetical) (Details)	Dec. 31, 2022	Oct. 24, 2022	Jun. 20, 2018
4.25% Senior Notes [Member]
Debt Instrument [Line Items]
Annual interest rate	4.25%	4.25%	4.25%

Debt - Additional Information (

Debt - Additional Information (Details)

1 Months Ended

3 Months Ended

9 Months Ended

Nov. 10, 2022 CAD ($)

Nov. 10, 2022 USD ($)

Oct. 24, 2022 USD ($) $ / shares

Jul. 18, 2022 shares

Jun. 29, 2022 CAD ($) shares

Jun. 22, 2022

Mar. 18, 2021 CAD ($)

Mar. 18, 2021 USD ($) $ / shares

Sep. 09, 2020 CAD ($)

Jun. 20, 2018 CAD ($) Trading_Day $ / shares

Sep. 09, 2020 CAD ($)

Oct. 19, 2018 CAD ($) $ / shares

Dec. 31, 2022 CAD ($)

Jun. 30, 2022 CAD ($) shares

Dec. 31, 2021 CAD ($)

Dec. 31, 2022 CAD ($)

Dec. 31, 2021 CAD ($)

Dec. 31, 2022 USD ($)

Nov. 10, 2022 USD ($)

Jul. 31, 2022 CAD ($) shares

Jun. 30, 2022 $ / shares

Jun. 29, 2022 $ / shares

Mar. 31, 2022 CAD ($)

Debt Instrument [Line Items]

Debt instrument discounted price

$ 930,000

$ 930,000

First repayment of debt

$ 117,951,000

$ 50,217,000

Minimum liquidity, each fiscal quarter

200,000,000

Reduced liquidity requirement

$ 100,000,000

Issuance of long-term debt

$ 893,160,000

Debt Instrument Fair Value

76,424,000

Debt instrument final closing trading days

10 days

Derivative liability

$ 39,896,000

39,896,000

Accretion Rate

11.06%

Conversion Of Outstanding Debentures Description

In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures.

Supreme Cannabis

Debt Instrument [Line Items]

Interest at a rate

6%

Maturity date

Sep. 10, 2025

Proceeds from the Credit Facility

$ 100,000,000

Cancellation of Debt

$ 63,500,000

Conversion price | $ / shares

$ 0.285

Monthly Interest Rate

1%

1%

Percentage of shares acquired

100%

Minimum [Member] | Supreme Cannabis

Debt Instrument [Line Items]

Proceeds from the Credit Facility

$ 13,500,000

Maximum | Supreme Cannabis

Debt Instrument [Line Items]

Interest at a rate

8%

Proceeds from the Credit Facility

$ 36,500,000

GCILP and Other Notes Holders [Member]

Debt Instrument [Line Items]

Principal amount

$ 199,522,000

4.25% Senior Notes [Member]

Debt Instrument [Line Items]

Principal amount

$ 262,620,000

$ 600,000,000

$ 337,380,000

$ 337,380,000

$ 600,000,000

Interest at a rate

4.25%

4.25%

4.25%

4.25%

4.25%

Frequency of periodic payment team

semi-annually on January 15th and July 15th of each year commencing from January 15, 2019

Maturity date

Jul. 15, 2023

Jul. 15, 2023

Accrued and unpaid interest

5,383,000

Aggregate purchase price

$ 259,994,000

Debt instrument cancelled

$ 0

$ 262,620,000

Debt Conversion, Description

(i) the market price of the Company’s common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $1 principal amount of the Notes for each trading day in the Measurement Period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by the CBI and its affiliates (together, the “CBI Group”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith

Conversion price percentage

130%

130%

Convertible measurement period threshold trading days

5 days

Convertible measurement period threshold consecutive trading days

5 days

Convertible conversion price | $ / shares

$ 1

Maximum discount to last reported sales price

98%

Debt instrument, redemption, description

Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law.

Debt instrument, redemption period, start date

Jul. 20, 2021

Debt instrument, redemption threshold trading days

20 days

Debt instrument, redemption threshold consecutive trading days

30 days

Number of trading days to provide notice of redemption

5 days

Debt instrument, redemption price, percentage

100%

Other income (expense), net

$ 44,370,000

Tax impact on aggregated principal amount

0

14,862,000

Debt instrument, change in fair value of notes

4,427,000

$ 16,806,000

238,403,000

120,372,000

Debt instrument, change in fair value of notes from contractual interest

3,583,000

$ 6,444,000

13,370,000

$ 19,128,000

Principal redemption

0

262,620,000

Principal redeemed fair value

0

225,369,000

4.25% Senior Notes [Member] | Exchange Transaction

Debt Instrument [Line Items]

Derivative liability

$ 26,594,000

4.25% Senior Notes [Member] | Minimum [Member]

Debt Instrument [Line Items]

Threshold consecutive trading days | Trading_Day

20

4.25% Senior Notes [Member] | Maximum

Debt Instrument [Line Items]

Threshold consecutive trading days | Trading_Day

30

4.25% Senior Notes [Member] | Common Shares

Debt Instrument [Line Items]

Principal amount

$ 63,098,000

$ 99,522,000

Shares issued | shares

35,662,420

14,069,353

21,593,067

Purchase price of shares | $ / shares

$ 3.50

Debt Instrument Fair Value

$ 50,866,000

4.25% Senior Notes [Member] | Common Shares | Noteholders [Member]

Debt Instrument [Line Items]

Shares issued | shares

11,896,536

Purchase price of shares | $ / shares

$ 2.6245

4.25% Senior Notes [Member] | Common Shares | GCILP [Member]

Debt Instrument [Line Items]

Principal amount

200,000,000

Shares issued | shares

29,245,456

Debt Instrument Fair Value

98,078,000

Debt instrument acquired

100,000,000

Debt instrument cancelled

$ 100,000,000

4.25% Senior Notes [Member] | Common Shares | GCILP and Other Notes Holders [Member]

Debt Instrument [Line Items]

Shares issued | shares

62,735,059

Paydown Agreement [Member]

Debt Instrument [Line Items]

Principal amount

100,000,000

Additional incremental term loan facility

500,000,000

Minimum liquidity, each fiscal quarter

$ 100,000,000

Share Issued on June and July 2022 [Member]

Debt Instrument [Line Items]

Principal amount

$ 262,620,000

$ 262,620,000

Shares issued | shares

76,804,412

Credit Facility

Debt Instrument [Line Items]

Senior secured debt, Term

5 years

Principal amount

$ 750,000

Debt instrument discounted price per us dollar | $ / shares

$ 1,000

$ 1,000

First repayment of debt

$ 174,375,000

$ 174,375,000

Senior credit facility

$ 500,000

Loan amortization payment

$ 0

Convertible debentures

Mar. 18, 2026

Credit Facility | Paydown Agreement [Member]

Debt Instrument [Line Items]

Principal amount

$ 187,500,000

$ 187,500

First repayment of debt

$ 117,528,000

$ 87,852,000

Aggregate principal payment amount

$ 126,324,000

$ 94,427,000

L I B O R Plus

Debt Instrument [Line Items]

Interest at a rate

8.50%

L I B O R Floor

Debt Instrument [Line Items]

Interest at a rate

1%

Other Liabilities - Components

Other Liabilities - Components of Other Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Current
Lease liabilities, current	$ 35,537	$ 38,035
Acquisition consideration and other investment related liabilities, current	7,908	4,020
Refund liability, current	2,937	3,437
Settlement liabilities and other, current	37,752	18,562
Other Liabilities Current	84,134	64,054
Long-term
Lease liabilities, long-term	83,167	101,125
Acquisition consideration and other investment related liabilities, long term	47,169	77,834
Settlement liabilities and other, long term	11,555	11,090
Other liabilities, long-term	141,891	190,049
Total
Lease liabilities	118,704	139,160
Acquisition consideration and other investment related liabilities	55,077	81,854
Refund liability	2,937	3,437
Settlement liabilities and other	49,307	29,652
Other liabilities	$ 226,025	$ 254,103

Other Liabilities - Additional

Other Liabilities - Additional Information (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Accelerated Share Repurchases [Line Items]
Settlement Liabilities And Other	$ 49,307	$ 29,652
Wana
Accelerated Share Repurchases [Line Items]
Estimated Deferred Payments	39,307	$ 70,066
TRA
Accelerated Share Repurchases [Line Items]
Settlement Liabilities And Other	$ 20,630

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interest - Summary of Net Changes in Redeemable Noncontrolling Interests (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	$ 36,200	$ 135,300
Net income (loss) attributable to redeemable noncontrolling interest	(17,808)	(13,100)
Adjustments to redemption amount	20,366	(48,391)
Ending balance	11,408	68,700
Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	(27,350)	(5,109)
Vert Mirabel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	1,000	11,500
Net income (loss) attributable to redeemable noncontrolling interest	508	(2,401)
Adjustments to redemption amount	(508)	(2,401)
Ending balance	1,000	11,500
BioSteel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	35,200	123,800
Net income (loss) attributable to redeemable noncontrolling interest	(18,316)	(10,699)
Adjustments to redemption amount	20,874	(50,792)
Ending balance	10,408	57,200
BioSteel | Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	$ (27,350)	$ (5,109)

Share Capital - Additional Info

Share Capital - Additional Information (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2022 CAD ($) Equity shares	Dec. 31, 2022 CAD ($) Equity shares	Dec. 31, 2021 CAD ($) Equity
Class of Stock [Line Items]
Number Of Equity Financing | Equity	0	0	0
Redemption of redeemable noncontrolling interest		$ (5,092)	$ (2,492)
BioSteel
Class of Stock [Line Items]
Shares issued relating to redemption of redeemable noncontrolling interest | shares	8,692,128	8,692,128
Redemption of redeemable noncontrolling interest	$ 26,506	$ 26,506
Percentage of interest before redemption	78.60%	78.60%
Percentage of interest after redemption	90.30%	90.30%

Share Capital - Summary of Issu

Share Capital - Summary of Issuances of Stock Other (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity Class Of Treasury Stock [Line Items]
Share based reserve	$ (1,732)
Completion of acquisition milestones, Number of shares	222,421	1,295,285
Share Capital
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ 1,379	$ 29,276
Share-based Reserve
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ (1,379)	$ (29,721)
Jetty Agreements
Equity Class Of Treasury Stock [Line Items]
Number of common shares	8,426,539
Share capital	$ 59,013
HSCP Holders Pursuant to Amended TRA [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	5,648,927
Share capital	$ 20,630
Acquisition Of Supreme Cannabis [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares		9,013,400
Share capital		$ 260,668
Other Issuances [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	237,802	351,252
Share capital	$ 1,209	$ 6,630
Share based reserve	$ (353)	$ (405)
Total [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	14,535,689	10,659,937
Share capital	$ 82,231	$ 296,574
Share based reserve		$ (30,126)

Share Capital - Summary of Warr

Share Capital - Summary of Warrants (Details) - CAD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Warrants And Rights Note Disclosure [Abstract]
Number of whole warrants, Beginning balance	128,193,047	127,073,136
Number of whole warrants, Supreme Cannabis Warrants		1,265,742
Number of whole warrants, Expiry of warrants		(145,831)
Number of whole warrants, Ending balance	128,193,047	128,193,047
Average exercise price, Beginning balance	$ 58.04	$ 58.33
Average exercise price, Supreme Cannabis warrants		25.61
Average exercise price, Expiry of warrants		$ 32.61
Average exercise price, Ending balance	$ 58.04	$ 58.04
Warrant value, Beginning balance	$ 2,581,788	$ 2,568,438
Warrant Value, Supreme Cannabis warrants		13,350
Warrant value, Expiry of warrants
Warrant value, Ending balance	$ 2,581,788	$ 2,581,788

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands			3 Months Ended			9 Months Ended
	May 27, 2021	Sep. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022	Oct. 01, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options extended period		10 years
Options maximum period		6 years
Weighted average exercise price of options outstanding			$ 27.07			$ 27.07		$ 33.89
Weighted average exercise price of options exercisable			$ 37.46			$ 37.46		$ 38.33
Share-based compensation expense				$ 971			$ 4,376
Options exercised						76,929
Exercise price						$ 3.41
Proceeds from exercise of stock options						$ 270	$ 5,455
Number of common shares released on completion of acquisition milestones			222,421	419,884		222,421	1,295,285
Number of shares to be issued on completion of acquisition and asset purchase milestones						125,489
Stock options outstanding			15,299,037			15,299,037		16,782,962
Share-based compensation			$ 6,428	$ 6,777		$ 21,725	$ 35,856
Supreme Cannabis
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense					$ 823
Bio Steel Sports Nutrition Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense			$ 373			$ 832	684
Percentage of outstanding shares purchased									72%
Stock options outstanding			924,719			924,719		1,565,300
Vesting period						5 years
Share-based compensation				160
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense			$ 1,790	3,696		$ 5,175	$ 22,038
Stock Option Subject To Performance Conditions
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense, options subject to performance conditions						1,078,748	1,559,413
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense			$ 4,265	$ 1,950		$ 15,718	$ 7,935
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares reserved for Awards			49,489,139			49,489,139
Options expiration period		10 years
Options exercised						76,929	421,476
Proceeds from exercise of stock options						$ 271	$ 5,455
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options vest on each anniversaries from date of grant		33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options vest on each anniversaries from date of grant		33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options vest on each anniversaries from date of grant		33.33%
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of common shares authorized			600,000			600,000
Equity shares issued to shareholders				0		237,802	61,103
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	15%
Maximum | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price						$ 8.18	$ 36.34
Maximum | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity shares issued to shareholders						300,000
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	10%
Minimum | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price						$ 0.06	$ 0.06

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Changes in Options Outstanding (Details)	9 Months Ended
	Dec. 31, 2022 $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, beginning balance | shares	16,782,962
Options granted | shares	4,651,176
Options exercised | shares	(76,929)
Options forfeited | shares	(6,058,172)
Options outstanding, ending balance | shares	15,299,037
Weighted average exercise price outstanding, beginning balance | $ / shares	$ 33.89
Weighted average exercise price, Options granted | $ / shares	4.94
Weighted average exercise price, Options exercised | $ / shares	3.41
Weighted average exercise price, Options forfeited | $ / shares	29.37
Weighted average exercise price outstanding, ending balance | $ / shares	$ 27.07

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Options Outstanding (Details) - $ / shares	9 Months Ended
	Dec. 31, 2022	Mar. 31, 2022
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding	15,299,037	16,782,962
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 3 months 7 days
Options Exercisable	9,330,692
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 2 months 8 days
Range One
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 0.06
Range of Exercise Prices, Upper Range	$ 24.62
Options Outstanding	6,083,908
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 9 months 29 days
Options Exercisable	1,369,076
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 9 months 7 days
Range Two
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 24.63
Range of Exercise Prices, Upper Range	$ 33.53
Options Outstanding	3,281,232
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 6 months 29 days
Options Exercisable	2,033,996
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 2 months 26 days
Range Three
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 33.54
Range of Exercise Prices, Upper Range	$ 36.80
Options Outstanding	1,569,568
Options Outstanding, Weighted Average Remaining Contractual Life	1 year 11 months 8 days
Options Exercisable	1,569,568
Options Exercisable, Weighted Average Remaining Contractual Life	1 year 11 months 8 days
Range Four
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 36.81
Range of Exercise Prices, Upper Range	$ 42.84
Options Outstanding	1,800,926
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 18 days
Options Exercisable	1,794,649
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 7 days
Range Five
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range	$ 42.85
Range of Exercise Prices, Upper Range	$ 67.64
Options Outstanding	2,563,403
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 1 month 6 days
Options Exercisable	2,563,403
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 1 month 6 days

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details) - $ / shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	3.47%	1.21%
Expected volatility	82%	75%
Expected forfeiture rate	20%	18%
Expected dividend yield
Black-Scholes value of each option	$ 3.34	$ 7.55
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	3 years	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	5 years	5 years

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of the Changes in RSUs and PSUs (Details) - RSUs	9 Months Ended
	Dec. 31, 2022 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	3,477,292
RSUs and PSUs granted	3,128,198
RSUs and PSUs released	(359,628)
RSUs and PSUs cancelled and forfeited	(1,925,026)
Ending balance	4,320,836

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 3,594,297	$ 3,486,520
Settlement of unsecured senior notes, net of tax	235,758
Ending balance	1,428,341	4,142,944
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(57,468)	(28,246)
Other comprehensive (loss) income	24,694	(18,767)
Ending balance	(32,774)	(47,013)
Changes of Own Credit Risk of Financial Liabilities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	15,186	(5,994)
Settlement of unsecured senior notes, net of tax	(29,507)
Other comprehensive (loss) income	32,847	26,280
Ending balance	18,526	20,286
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(42,282)	(34,240)
Settlement of unsecured senior notes, net of tax	(29,507)
Other comprehensive (loss) income	57,541	7,513
Ending balance	$ (14,248)	$ (26,727)

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Minority Interest [Line Items]
Beginning balance			$ 3,594,297	$ 3,486,520
Comprehensive income (loss)	$ (5,139)	$ (6,571)	(19,652)	(14,307)
Net (income) loss attributable to redeemable noncontrolling interest			17,808	13,100
Share-based compensation	6,428	6,777	21,725	35,856
Ending balance	1,428,341	4,142,944	1,428,341	4,142,944
Noncontrolling Interests
Minority Interest [Line Items]
Beginning balance			4,341	4,709
Comprehensive income (loss)			(19,652)	(14,307)
Net (income) loss attributable to redeemable noncontrolling interest			17,808	13,100
Share-based compensation			495	684
Ownership changes			(196)
Ending balance	2,796	4,186	2,796	4,186
Vert Mirabel
Minority Interest [Line Items]
Comprehensive income (loss)			508	(2,401)
Net (income) loss attributable to redeemable noncontrolling interest			(508)	2,401
BioSteel
Minority Interest [Line Items]
Beginning balance			2,497	1,658
Comprehensive income (loss)			(18,316)	(10,699)
Net (income) loss attributable to redeemable noncontrolling interest			18,316	10,699
Share-based compensation			495	684
Ownership changes			(1,552)
Ending balance	1,440	2,342	1,440	2,342
Other
Minority Interest [Line Items]
Beginning balance			1,844
Comprehensive income (loss)			(1,844)
Ownership changes			1,356
Ending balance	$ 1,356		$ 1,356
Other Non-material Interests
Minority Interest [Line Items]
Beginning balance				3,051
Comprehensive income (loss)				(1,207)
Ending balance		$ 1,844		$ 1,844

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Assets:
Short-term investments	$ 191,119	$ 595,651
Restricted short-term investments	12,932	12,216
Other financial assets	509,064	788,306
Liabilities:
Unsecured senior notes	325,555	563,958
Derivative liability	668
Other liabilities	43,102	70,066
Acreage
Liabilities:
Derivative liability		47,000
Warrant
Liabilities:
Derivative liability		26,920
Level 1
Assets:
Short-term investments	191,119	595,651
Restricted short-term investments	12,932	12,216
Other financial assets	251	490
Level 2
Liabilities:
Unsecured senior notes	325,555	563,958
Level 3
Assets:
Other financial assets	508,813	787,816
Liabilities:
Derivative liability	668
Other liabilities	$ 43,102	70,066
Level 3 | Acreage
Liabilities:
Derivative liability		47,000
Level 3 | Warrant
Liabilities:
Derivative liability		$ 26,920

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 Financial Instruments (Details) - Level 2 - Unsecured Senior Notes	9 Months Ended
	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Senior note pricing model
Key inputs	Quoted prices in over-the-counter broker market

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments (Details) - Level 3	9 Months Ended
	Dec. 31, 2022
Acreage Financial Instrument Probability of Each Scenario
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Probability weighted expected return model
Significant unobservable inputs	Probability of each scenario
Relationship of unobservable inputs to fair value	Change in probability of occurrence in each scenario will result in a change in fair value
Acreage Financial Instrument Value and Number of Canopy Shares Issued
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Number of common shares to be issued
Relationship of unobservable inputs to fair value	Increase or decrease in value and number of common shares will result in a decrease or increase in fair value
Acreage Financial Instrument Intrinsic Value of Acreage
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Probability and Timing of US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Estimated premium on US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Estimated Premium on US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Control premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated control premium will result in an increase or decrease in fair value
Acreage Financial Instrument Control Premium
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Market access premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated market access premium will result in an increase or decrease in fair value
TerrAscend Exchangeable Shares, TerrAscend Option
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Put option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Hempco Debenture
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
TerrAscend warrants - December 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Black-Sholes option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Wana Financial Instrument - Call Option
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Expected future Wana cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value
Wana Financial Instrument - Call Option, Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Wana Financial Instrument - Deferred Payments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Wana Financial Instrument Volatility of Wana Equity
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Volatility of Wana equity
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Warrant Derivative Liability Volatility of Canopy Growth Share Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Volatility of Canopy Growth share price
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
BioSteel Redeemable Noncontrolling Interest Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
BioSteel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Expected future BioSteel cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value
Jetty Financial Instrument - Call Option
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Expected future Jetty cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future Jetty cash flows will result in an increase or decrease in fair value
Jetty Financial Instrument - Call Option, Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Jetty Financial Instrument - Deferred Payments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Jetty Financial Instrument Volatility of Jetty Equity and Revenue
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Volatility of Jetty equity and revenue
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Future wholesale price and production levels
Relationship of unobservable inputs to fair value	Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Details) - CAD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Gross revenue		$ 113,349	$ 155,024	$ 366,570	$ 456,095
Net revenue		101,213	140,972	329,191	408,555
Canadian adult-use Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		32,558	47,759	109,622	166,375
Canadian Medical Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	[1]	14,059	12,919	41,714	39,504
Canadian Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		46,617	60,678	151,336	205,879
Rest-of-world Cannabis
Disaggregation Of Revenue [Line Items]
Gross revenue		5,846	22,299	30,179	65,362
Net revenue		5,846	22,299	30,179	65,362
C3 | Rest-of-world Cannabis
Disaggregation Of Revenue [Line Items]
Gross revenue			9,675		33,005
Other rest-of-world cannabis | Rest-of-world Cannabis
Disaggregation Of Revenue [Line Items]
Gross revenue		5,846	12,624	30,179	32,357
Business to Business | Canadian adult-use Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	[2]	21,522	33,282	73,379	117,902
Business to Consumer | Canadian adult-use Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue		11,036	14,477	36,243	48,473
Other
Disaggregation Of Revenue [Line Items]
Gross revenue		3,884	5,086	13,475	16,073
Storz & Bickel
Disaggregation Of Revenue [Line Items]
Gross revenue		20,214	25,205	49,351	63,786
This Work
Disaggregation Of Revenue [Line Items]
Gross revenue		8,289	10,730	20,677	26,308
BioSteel
Disaggregation Of Revenue [Line Items]
Gross revenue		$ 16,363	$ 16,974	$ 64,173	$ 31,147
[1] Canadian medical cannabis net revenue for the three and nine months ended December 31, 2022 reflects excise taxes of $ 1,339 and $ 3,625 , respectively (three and nine months ended December 31, 2021 – $ 1,298 and $ 4,039 , respectively). Canadian adult-use business-to-business net revenue during the three and nine months ended December 31, 2022 reflects excise taxes of $ 10,797 and $ 33,754 , respectively (three and nine months ended December 31, 2021 – $ 12,754 and $ 43,501 , respectively).

Revenue - Summary of Disaggre_2

Revenue - Summary of Disaggregation of Revenue (Parenthetical) (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Net revenue	$ 101,213	$ 140,972	$ 329,191	$ 408,555
CANADA
Disaggregation Of Revenue [Line Items]
Net revenue	65,851	78,644	226,312	241,440
CANADA | Recreational Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	10,797	12,754	33,754	43,501
CANADA | Medical Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	$ 1,339	$ 1,298	$ 3,625	$ 4,039

Revenue - Additional Informatio

Revenue - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Allowance for estimated returns and price adjustments	$ 8,869	$ 3,726	$ 15,345	$ 12,375
Liability for estimated returns and price adjustments	$ 2,937		$ 2,937		$ 3,437

Other Income (Expense), Net - S

Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Other Income And Expenses [Abstract]
Fair value changes on other financial assets	$ (95,815)	$ (68,666)	$ (396,755)	$ (263,946)
Fair value changes on liability arising from Acreage Arrangement		59,000	47,000	497,000
Fair value changes on unsecured senior notes	(8,964)	606	(32,365)	81,342
Fair value changes on warrant derivative liability	23	67,282	26,252	578,084
Fair value changes on acquisition related contingent consideration and other	1,762	712	25,902	544
Gain (loss) and charges related to settlement of debt	8,912		4,224
Interest income	7,048	1,575	15,922	6,977
Interest expense	(33,288)	(26,408)	(90,660)	(77,618)
Foreign currency gain (loss)	2,966	990	(8,828)	2,902
Gain (loss) on disposal/acquisition of consolidated entity	4,142		6,223	(1,653)
Other income (expense), net	(126)	(809)	(3,677)	(12,863)
Other income (expense), net	$ (113,340)	$ 34,282	$ (406,762)	$ 810,769

Earnings (Loss) Per Share - Com

Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings (Loss) Per Share (Details) - CAD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Basic (loss) earnings per share computation
Net (loss) income attributable to common shareholders of Canopy Growth	$ (261,583)	$ (108,925)	$ (2,566,537)	$ 272,435
Weighted average number of common shares outstanding	486,112,598	393,818,282	453,237,882	390,423,083
Basic (loss) earnings per share	$ (0.54)	$ (0.28)	$ (5.66)	$ 0.70
Diluted (loss) earnings per share computation
Net (loss) income used in the computation of basic (loss) earnings per share	$ (261,583)	$ (108,925)	$ (2,566,537)	$ 272,435
Adjustment to net loss attributable to noncontrolling interests and redeemable noncontrolling interest				(13,100)
Removal of fair value changes on unsecured senior notes				(81,342)
Net (loss) income used in the computation of diluted (loss) earnings per share	$ (261,583)	$ (108,925)	$ (2,566,537)	$ 177,993
Weighted average number of common shares outstanding	486,112,598	393,818,282	453,237,882	390,423,083
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding	486,112,598	393,818,282	453,237,882	410,986,802
Diluted (loss) earnings per share	$ (0.54)	$ (0.28)	$ (5.66)	$ 0.43
Unsecured Senior Notes [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				12,454,620
Redeemable Noncontrolling Interest [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				4,528,898
Stock Option 1 [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				745,700
Other Securities [Member]
Dilutive impact of assumed exercise or conversion of:
Diluted weighted average common shares outstanding				2,834,501

Aquisition - Summary of Consoli

Aquisition - Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combination (Details) - Verona Manufacturing Facility $ in Thousands	9 Months Ended
	Dec. 31, 2022 CAD ($)
Business Acquisition [Line Items]
Property, plant and equipment	$ 28,771
Debt and other liabilities	(2,373)
Net assets acquired	26,398
Consideration paid in cash	24,223
Other consideration	2,175
Total consideration	26,398
Net cash outflow	$ 24,223

Acquisition - Additional Inform

Acquisition - Additional Information (Details) - Verona Manufacturing Facility $ in Thousands, $ in Thousands			9 Months Ended
	Nov. 08, 2022 CAD ($)	Nov. 08, 2022 USD ($)	Dec. 31, 2022 CAD ($)
Business Acquisition [Line Items]
Consideration			$ 26,398
Consideration paid in cash			$ 24,223
Verona, Virginia
Business Acquisition [Line Items]
Consideration	$ 26,398	$ 19,477
Consideration paid in cash	15,685	11,573
Consideration transferred related to repayment of debt and retirement of certain lease obligations	8,538	6,299
Consideration transferred in remediation and indemnity holdbacks	$ 2,175	$ 1,605

Retail Divestiture - Additional

Retail Divestiture - Additional Information (Details) $ in Thousands		3 Months Ended
	Dec. 30, 2022 RetailStore	Dec. 31, 2022 CAD ($)
OEGRC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of ownership acquired | RetailStore	23
OEGRC and FOUR20
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses		$ 88
Deferred consideration		5,500
Earnout payment receivable		$ 6,099

Retail Divestiture - Summary of

Retail Divestiture - Summary of Derecognized Assets and Liabilities Transferred (Details) - OEGRC and FOUR20 $ in Thousands	3 Months Ended
	Dec. 31, 2022 CAD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets	$ 6,461
Property, plant and equipment	7,990
Other long-term assets	144
Current liabilities	(9,492)
Net assets disposed	5,103
Consideration received in cash	88
Future cash consideration	11,599
Costs to sell	(2,442)
Total consideration	9,245
Gain on disposal of consolidated entity	$ 4,142

Acreage Arrangement and Amend_2

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands						9 Months Ended
	Oct. 24, 2022 CAD ($) shares	Sep. 23, 2020 CAD ($)	Sep. 23, 2020 USD ($) $ / shares	Jun. 27, 2019 CAD ($)	Jun. 27, 2019 USD ($)	Dec. 31, 2022 CAD ($) shares	Dec. 31, 2022 USD ($)	Dec. 09, 2022 CAD ($)	Mar. 31, 2022 CAD ($) shares	Jun. 24, 2020 shares	Apr. 18, 2019 $ / shares shares
Business Acquisition [Line Items]
Derivative, financial liability						$ 668,000			$ 26,920,000
Debentures bear interest rate per annum						6.10%
Estimated fair value								$ 89,094,000
Warrant expiration date								Dec. 31, 2032			Nov. 01, 2023
Common stock, shares issued | shares						494,891,390			394,422,604
Cancellation consideration						$ 7,867,310,000			$ 7,482,809,000
Tranche A Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares											88,500,000
Exercise price of warrants | $ / shares											$ 50.40
Tranche B Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares											38,500,000
Exercise price of warrants | $ / shares											$ 76.68
Tranche C Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares											12,800,000
Tranche B and C Warrants | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Number of common stock shares to be repurchased to avoid providing repurchase credit | shares						27,378,866
Value of common stock to be repurchased to avoid providing repurchase credit						$ 1,583,000,000
Derivative liability						0
Debenture
Business Acquisition [Line Items]
Payments to acquire investments						66,995,000	$ 50,000
Estimated fair value						27,853,000			28,824,000
Additional payment upon satisfaction of certain conditions							$ 50,000
Warrants
Business Acquisition [Line Items]
Derivative, financial liability						$ 668,000			26,920,000
Common stock, shares issued | shares	139,745,453					139,745,453
Cancellation consideration						$ 0
Maximum | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Share repurchase credit limit						1,583,000,000
Acreage
Business Acquisition [Line Items]
Aggregate payment		$ 49,849,000	$ 37,500	$ 395,190,000	$ 300,000
Cancellation consideration	$ 19,559,000
Acreage | Acreage Financial Instrument
Business Acquisition [Line Items]
Derivative, financial liability									$ 47,000,000
Derivative,financial asset						$ 37,000,000
Acreage | Maximum
Business Acquisition [Line Items]
Number Of Fixed And Floating Shares Issued | shares										32,700,000
Acreage | Fixed Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.3048
Acreage | Class E Subordinated Voting Shares | Fixed Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.3048	0.3048	0.3048
Acreage | Class D Subordinated Voting Shares | Floating Shares
Business Acquisition [Line Items]
Minimum call price | $ / shares			$ 6.41

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended			9 Months Ended
	Dec. 31, 2022 Customer	Sep. 30, 2022 Segment	Dec. 31, 2021 Customer	Dec. 31, 2022 Customer	Dec. 31, 2021 Customer
Segment Reporting Information [Line Items]
Number of operating segments | Segment		2
Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk customer number of customers | Customer	0		0	0	1

Segment Information - Summary o

Segment Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenue	$ 101,213	$ 140,972	$ 329,191	$ 408,555
Gross margin	(2,441)	10,090	(12)	(33,812)
Selling, general and administrative expenses	122,636	116,835	351,891	355,165
Share-based compensation	6,428	6,777	21,725	35,856
Asset impairment and restructuring costs	22,259	36,439	1,794,212	128,198
Operating loss	(153,764)	(149,961)	(2,167,840)	(553,031)
Loss from equity method investments				(100)
Other income (expense), net	(113,340)	34,282	(406,762)	810,769
(Loss) income before income taxes	(267,104)	(115,679)	(2,574,602)	257,638
Canada Cannabis
Segment Reporting Information [Line Items]
Net revenue	46,617	60,678	151,336	205,879
Gross margin	(5,281)	(13,121)	(25,466)	(97,925)
Rest-of-world Cannabis
Segment Reporting Information [Line Items]
Net revenue	5,846	22,299	30,179	65,362
Gross margin	(2,184)	4,660	(3,676)	24,245
Storz & Bickel
Segment Reporting Information [Line Items]
Net revenue	20,214	25,205	49,351	63,786
Gross margin	9,186	11,172	20,809	27,623
BioSteel
Segment Reporting Information [Line Items]
Net revenue	16,363	16,974	64,173	31,147
Gross margin	(7,669)	1,352	(804)	(2,361)
This Works
Segment Reporting Information [Line Items]
Net revenue	8,289	10,730	20,677	26,308
Gross margin	4,032	5,469	8,982	12,423
Other
Segment Reporting Information [Line Items]
Net revenue	3,884	5,086	13,475	16,073
Gross margin	$ (525)	$ 558	$ 143	$ 2,183

Segment Information - Summary_2

Segment Information - Summary of Disaggregation of Net Revenue by Geographic Area (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 101,213	$ 140,972	$ 329,191	$ 408,555
CANADA
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	65,851	78,644	226,312	241,440
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	12,772	23,143	36,383	71,619
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	10,292	22,764	30,688	60,856
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 12,298	$ 16,421	$ 35,808	$ 34,640

Segment Information - Summary_3

Segment Information - Summary of Disaggregation of Property, Plant and Equipment by Geographic Area (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	$ 874,029	$ 942,780
CANADA
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	726,613	827,591
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	96,159	63,247
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	$ 51,257	$ 51,942

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)	9 Months Ended
	Dec. 31, 2022
Facility Closing
Subsequent Event [Line Items]
Facility closing discription	The Company intends to close the 1 Hershey Drive facility in Smiths Falls, Ontario